Process for preparing arimoclomol citrate and its intermediates
Patent Information
- Application Number
- JP2023530749
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-06-17
- Filing Date
- 2021-11-19
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000141_0000
Abstract
Description
[Technical field]
[0001] The present disclosure relates to processes for the preparation of arimoclomol, arimoclomol citrate, and key intermediates thereof, such as ORZY-01.The present disclosure further relates to processes for the preparation of high purity arimoclomol citrate and methods of use thereof. [Background technology]
[0002] Arimoclomol citrate is an active pharmaceutical ingredient (API) for the treatment of lysosomal storage diseases, including Niemann-Pick disease type C. Summary of the Invention
[0003] The present disclosure provides an optimized four-step process for preparing an ultra-pure composition comprising arimoclomol citrate, i.e., N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate. The optimized process includes multiple optimized sub-steps, each of which contributes to improving the overall process, to provide an ultra-pure composition comprising arimoclomol citrate. The ultra-pure composition comprising arimoclomol citrate meets the stringent regulatory requirements of drug authorities. The four-step process is outlined below: [ka] Step 1: Overview of the preparation process of ORZY-01 [ka] Step 2: Overview of the preparation process for ORZY-03 [ka] Step 3: Overview of the preparation process of crude BRX-345 (ORZY-04) [ka] Step 4: Overview of the preparation process of BRX-345 (ORZY-05)
[0004] The disclosed methods contribute to both controlling the chiral purity (i.e., enantiomeric excess) of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate to exceed thresholds set by regulatory agencies and that the ultra-pure composition is essentially free of previously identified by-products, e.g., RRT 0.74, and N-nitrosopiperidine.
[0005] The chiral purity of the ultra-pure composition comprising arimoclomol citrate is the result of a chiral resolution step, i.e., a process according to "Step 2" of the present disclosure. The present disclosure provides a correlation between the cooling rate of the crude reaction mixture in Step 2 and the chiral purity of ORZY-03 (see Examples 4 and 5). The chiral purity of ORZY-03 obtained in Step 2 is retained through to the final product, but can be further improved by recrystallization.
[0006] The present disclosure has identified a by-product RRT 0.74 that occurs during the salt exchange in step 3 of preparing "crude BRX-345" from ORZY-03, as shown below. [ka] (RRT 0.74, methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide)
[0007] The present disclosure provides an improved process incorporating an aqueous wash and the addition of catalytic amounts of citric acid, which in some embodiments removes the by-product RRT 0.74 without significant loss in yield of the desired product.
[0008] Additionally, the present disclosure provides an optimized process for making ORZY-01, [ka] It provides ORZY-01 in high (up to 80%) yield and purity while reducing the hazards of large-scale processes.
[0009] The previously reported two-step synthesis of ORZY-01, shown below, involves refluxing for 2 hours in step 1A, followed by purification of intermediate compound (V) to improve batch quality. [ka]
[0010] Furthermore, the previously reported next step from compound (V) to ORZY-01, which was carried out at -5 °C to 0 °C, required several doses of sodium nitrite to drive the reaction to completion, which delayed the exothermic reaction and generated gas, raising safety concerns during scale-up.
[0011] The process of the present disclosure improves upon the reaction in Step 1A, allowing for subsequent conversion of compound (V) directly to ORZY-01 without isolation. Additionally, Step 1B of the present disclosure proceeds to completion with a single charge of sodium nitrite in a safe and controllable operation, without gas evolution delays and process chemistry hazards.
[0012] In a first aspect, a process for preparing ORZY-01 is provided, [ka] The process comprises: Step 1A) Reacting a compound of formula (I), [ka] with a compound of formula (II), [ka] in a first solvent at a first temperature for more than two hours to obtain an intermediate; and Step 1B) reacting the intermediate with NaNO2 in a second solvent at a second temperature to obtain ORZY-01, thereby obtaining ORZY-01.
[0013] In a second aspect, ORZY-01, [ka] and one or more impurities selected from the group consisting of: [ka]
[0014] In a third aspect, there is provided a process for preparing arimoclomol citrate, comprising: [ka] The process comprises the process defined herein for obtaining ORZY-01, [ka] subsequently precipitating ORZY-01 with dibenzoyl L-tartaric acid to obtain ORZY-03; [ka] This involves reacting ORZY-03 with a base and then precipitating the resulting ORZY-03 free base with citric acid to obtain arimoclomol citrate.
[0015] In a fourth aspect, there is provided a process for preparing arimoclomol citrate, comprising: [ka] The process includes the process defined herein for obtaining ORZY-01.
[0016] In one aspect, the present disclosure relates to an oral formulation comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient.
[0017] In some embodiments, the pharma- ceutically acceptable salt of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide is N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0018] In one aspect, the disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, having a purity of 98.0% or greater.
[0019] In one aspect, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of an oral formulation, pharmaceutical composition, or unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof.
[0020] In one aspect, the disclosure provides an oral formulation, pharmaceutical composition, or unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0021] In one aspect, the disclosure provides use of an oral formulation, pharmaceutical composition, or unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0022] In one aspect, the disclosure provides use of an oral formulation, pharmaceutical composition, or unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. Methods and materials similar or equivalent to those described herein can be used to carry out or test this disclosure, and suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will take precedence. Moreover, the materials, methods, and examples are merely illustrative and are not intended to be limiting.
[0024] Other features and advantages of the disclosure will become apparent from the following detailed description, and from the claims. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] definition To facilitate understanding of the following discussion, some definitions are provided in the following paragraphs.
[0026] As used herein, the term "polar protic solvent" refers to a polar solvent that is capable of exchanging protons with a reagent and contains a polarizable proton. Examples of polar protic solvents are butanol, 2-propanol, propanol, ethanol, methanol, water and mixtures thereof.
[0027] As used herein, the term "pharmaceutical acceptable salt" refers to salts that are commonly used in the pharmaceutical field. Examples of pharmaceutical acceptable salts include, but are not limited to, sodium salt, hydrochloride, magnesium salt, calcium salt, trifluoroacetate salt and potassium salt. Further exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, salicylate, acid citrate, tartrate, tartrate, olcate, tannate, pantothenate, bitartrate, ascorbate, succinate, malcate, gentisate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate.
[0028] The term "chlorinated hydrocarbon" refers to a hydrocarbon in which one or more hydrogen atoms have been replaced with chlorine. Examples of chlorinated hydrocarbons are intended to include, but are not limited to, dichloromethane, chloroform, carbon tetrachloride, and dichloroethane. Dichloromethane is also known as DCM or CH2Cl2.
[0029] As used herein, the term "ethanol" should be understood to include ethanol having a purity of at least 95% by weight, denatured ethanol, and hydrous ethanol containing 20-5% by weight of water. An example of the denatured ethanol is a mixture of 95% by weight ethanol and 5% by weight isopropyl alcohol, and an example of the hydrous ethanol is a mixture of 83% by weight ethanol and 17% by weight purified water.
[0030] As used herein, the term "PCO-N-oxide" refers to the compound N-hydroxy-1-oxy-nicotinamidine. The structure of PCO-N-oxide is shown in formula (I) herein.
[0031] As used herein, the term "azonia" refers to the compound azonia-spiro[3,5]nonane chloride. The structure of azonia is shown in formula (II) herein.
[0032] As used herein, the term "boiling point" refers to the boiling point of a liquid at 760 mm / Hg, or ±2° C. deviation therefrom.
[0033] As used herein, the term "about" refers to a recited amount, value, or time period ±10% or less of the recited amount, value, or time period. In some embodiments, "about" refers to the recited amount, value, or time period ±10%, ±8%, ±6%, ±5%, ±4%, ±2%, ±1%, or ±0.5%. In other embodiments, "about" refers to the recited amount, value, or time period ±10%, ±8%, ±6%, ±5%, ±4%, or ±2%. In other embodiments, "about" refers to the recited amount, value, or time period ±5%. In some embodiments, "about" refers to the recited amount, value, or time period ±2% or ±1%. For example, in some embodiments, when the term "about" is used in reciting a temperature or temperature range, the term refers to the recited temperature or temperature range ±5°C, ±2°C, or ±1°C. In other embodiments, the term "about" refers to the recited temperature or temperature range ±2°C.
[0034] As used herein, "arimoclomol" refers to a compound having the following structure: [ka] Also referred to herein as N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide.
[0035] As used herein, "arimoclomol S-enantiomer" refers to a compound of the following structure: [ka] Also referred to herein as N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide.
[0036] As used herein, "arimoclomol citrate" refers to a compound having the following structure: [ka] Also referred to herein as "N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate," "ORZY-05," or "BRX-345."
[0037] As used herein, "RRT 0.74" refers to a compound of the following structure: [ka] Also referred to herein as methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide.
[0038] As used herein, the term "vessel" refers to all or part of a unit of a manufacturing facility in which the chemical reactions used to form the molecules described herein, such as ORZY-01, ORZY-03, ORZY-04, or ORZY05, are carried out.
[0039] As used herein, "treating" or "treat" refers to the management and care of a patient for the purpose of combating a disease, condition, or disorder, and includes administering a compound of the disclosure (e.g., N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate) to alleviate the symptoms or complications of the disease, condition, or disorder, or to eliminate the disease, condition, or disorder. The term "treat" can also include the treatment of in vitro cells or animal models.
[0040] The compounds of the present disclosure (e.g., N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate) can also be used to prevent a disease, condition, or disorder, or to identify suitable candidates for such purposes. As used herein, "preventing" or "preventing" refers to reducing or eliminating the onset of symptoms or complications of a disease, condition, or disorder.
[0041] Process and Conditions Seed crystal preparation Seed crystals of any of ORZY-01, ORZY-03, and ORZY-05 can be prepared by preparative high performance liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) separation of a racemic mixture to provide enantiomerically enriched ORZY-01 with chiral purity of greater than about 95%. Seed crystals of the enantiomerically enriched ORZY-01 obtained from HPLC or SFC can be grown from a suitable solvent. The enantiomerically enriched ORZY-01 can then be precipitated in a suitable solvent with L-DBTA to obtain seeds of ORZY-03. The enantiomerically enriched ORZY-01 can then be precipitated in a suitable solvent with citric acid to obtain seeds of ORZY-05.
[0042] In some embodiments, the process disclosed herein further comprises adding one or more seed crystals of ORZY-01 to the vessel. In some embodiments, the process disclosed herein further comprises adding one or more seed crystals of ORZY-03 to the vessel. In some embodiments, the process disclosed herein further comprises adding one or more seed crystals of ORZY-05 to the vessel.
[0043] In some embodiments, the seeds are added during the preparation of an intermediate of the present disclosure.
[0044] In some embodiments, the process disclosed herein further comprises, as a first step, adding one or more seed crystals of ORZY-01 to the vessel. In some embodiments, the process disclosed herein further comprises, as a first step, adding one or more seed crystals of ORZY-03 to the vessel. In some embodiments, the process disclosed herein further comprises, as a first step, adding one or more seed crystals of ORZY-05 to the vessel.
[0045] Step 1 (ORZY-01) As demonstrated by Example 1 of the present disclosure, by optimizing the reaction conditions, reaction ratios, reaction times, and temperatures, it was possible to isolate the product ORZY-01 in 79.6% yield without isolating intermediates, which is higher than that reported previously.
[0046] In some embodiments, a process for preparing ORZY-01 is provided, comprising: [ka] The process comprises: Step 1A) Reacting a compound of formula (I), [ka] with a compound of formula (II), [ka] and mixing the intermediate with NaNO2 in a first solvent at a first temperature for more than two hours to obtain an intermediate, and then step 1B) reacting the intermediate with NaNO2 in a second solvent at a second temperature to obtain ORZY-01.
[0047] In some embodiments, the preparation process of ORZY-01 is carried out in a container. Thus, the steps described in the process can be carried out in the container. Those skilled in the art can select the appropriate container according to the batch size.
[0048] In some embodiments, a process for preparing ORZY-01 is provided, comprising: [ka] The process comprises: Step 1A) Reacting a compound of formula (I), [ka] a compound of formula (II) contained in a container, [ka] in a first solvent at a first temperature to obtain an intermediate, and then, step 1B) reacting the intermediate with NaNO2 in a second solvent at a second temperature to obtain ORZY-01.
[0049] In some embodiments, a process is provided in which the intermediate is isolated and optionally purified prior to step 1B).
[0050] In some embodiments, a process is provided in which the first solvent is a polar protic solvent or a mixture of polar protic solvents.
[0051] In some embodiments, the first solvent is selected from the group consisting of ethanol, water, methanol, 2-propanol, and any mixture thereof, hi some embodiments, the first solvent is a mixture of ethanol and water.
[0052] In some embodiments, a process is provided in which step 1A is carried out under basic conditions, for example by addition of a hydroxide, for example NaOH or KOH, for example NaOH (50% by weight) in an aqueous solution.
[0053] In some embodiments, the process as defined herein is provided, wherein the second solvent is a chlorinated hydrocarbon or a mixture comprising a chlorinated hydrocarbon, hi some embodiments, the second solvent is a mixture of dichloromethane and water.
[0054] In some embodiments, the process provides that the first solvent is different from the second solvent.
[0055] In some embodiments, a process is provided in which the first temperature is the boiling point of the solvent.
[0056] Some embodiments provide a process in which the first temperature is greater than the second temperature.
[0057] In some embodiments, the first temperature is about 70° C. to about 90° C., for example, about 72° C. to about 88° C., for example, about 74° C. to about 86° C., for example, about 76° C. to about 84° C., for example, about 78° C. to about 82° C., for example, about 80° C. In some embodiments, the first temperature is about 75° C. to about 85° C., for example, about 80° C. In some embodiments, the first temperature is maintained for about 3.5 hours or more.
[0058] In some embodiments, the second temperature is from about 0°C to about 15°C, for example, from about 6°C to about 14°C, for example, from about 7°C to about 13°C, for example, from about 8°C to about 12°C, for example, from about 9°C to about 11°C, for example, about 10°C.
[0059] In some embodiments, the second temperature is about 0° C. or higher, such as greater than about 0° C. In one embodiment, the second temperature is about 15° C. or lower.
[0060] In some embodiments, the second temperature is about 0°C to about 15°C, for example, about 0°C to about 1°C, for example, about 1°C to about 2°C, for example, about 2°C to about 3°C, for example, about 3°C to about 4°C, for example, about 5°C to about 6°C, for example, about 6°C to about 7°C, for example, about 7°C to about 8°C, for example, about 8°C to about 9°C, for example, about 9°C to about 10°C, for example, about 10°C to about 11°C, for example, about 11°C to about 12°C, for example, about 12°C to about 13°C, for example, about 13°C to about 14°C, for example, about 14°C to about 15°C.
[0061] In some embodiments, the second temperature is maintained for about 1 hour.
[0062] In some embodiments, a compound of formula (II): [ka] in a molar ratio of 1.3:1.0, a compound of formula (I), [ka] and mixing the same with the process defined herein.
[0063] In some embodiments, the compound of formula (II) is mixed with the compound of formula (I) in a molar ratio of 1.2:1.0 to 2.0:1.0, such as 1.2:1.0 to 1.3:1.0, for example, 1.3:1.0 to 1.4:1.0, for example, 1.4:1.0 to 1.5:1:0, for example, 1.5:1.0 to 1.6:1.0, for example, 1.6:1.0 to 1.7:1.0, for example, 1.7:1.0 to 1.8:1.0, for example, 1.8:1.0 to 1.9:1.0, for example, 1.9:1.0 to 2.0:1.0.
[0064] In some embodiments, the intermediate is not isolated prior to reaction with NaNO2. In some embodiments, the intermediate that is not isolated prior to reaction with NaNO2 refers to compound (V) disclosed herein and can be obtained directly from step 1A. In some embodiments, the intermediate is represented by formula (V): [ka] or a pharma- ceutically acceptable salt thereof.
[0065] In some embodiments, the intermediate is reacted with 1.2 to 1.6 equivalents of NaNO2, such as 1.2 to 1.3 equivalents, such as 1.3 to 1.4 equivalents, such as 1.4 to 1.5 equivalents, for example, 1.5 to 1.6 equivalents.
[0066] In some embodiments, the intermediate is reacted with at least 1.2 equivalents of NaNO 2 .
[0067] In some embodiments, the first temperature results in reflux of the first solvent, and optionally the first temperature results in reflux of the first solvent for 2.5 hours or more, e.g., 3 hours or more, e.g., 4 hours or more, e.g., 5 hours or more, e.g., 6 hours or more. In this aspect, "the first temperature results in reflux" means the first temperature is at or sufficiently close to the boiling point of the first solvent such that condensed vapors form and a condensate is formed that is returned to the system in which it originates.
[0068] In some embodiments, the first solvent is heated to about 75° C. to about 85° C. for at least 3.5 hours.
[0069] In some embodiments, the first solvent is heated to about 75° C. to about 85° C. for 3.5 hours to 4.5 hours, e.g., 3.5 hours to 4.0 hours, e.g., 4.0 hours to 4.5 hours. In one embodiment, the first temperature is 75° C. to 85° C. for 3.5 hours to 4.5 hours, e.g., 3.5 hours to 4.0 hours, e.g., 4.0 hours to 4.5 hours.
[0070] In some embodiments, the first solvent is a mixture of ethanol and water, optionally denatured, and the first solvent is maintained for more than 2 hours at 80° C. In some embodiments, the first solvent is a mixture of ethanol and water, optionally denatured, and the first solvent is maintained at about 80° C. for at least 3 hours.
[0071] Ethanol can be used in both denatured and undenatured forms. In Example 1 of the present disclosure, the denatured form was used successfully. The undenatured form has also been found to be successful. Data for the undenatured form is not presented here.
[0072] In some embodiments, the first solvent is a mixture of ethanol and water, optionally denatured, the first solvent is maintained at about 80° C. for more than 2 hours, and the second solvent is a mixture of dichloromethane and water. In one embodiment, the first solvent is a mixture of ethanol and water, optionally denatured, the first solvent is maintained at about 80° C. for at least 3 hours, and the second solvent is a mixture of dichloromethane and water.
[0073] Drying ORZY-01 In some embodiments, the wet product from the preparation process of ORZY-01 is dried under vacuum. In some embodiments, the wet product is dried at less than 45° C. for at least 8 hours, e.g., overnight. In some embodiments, the wet product is dried at 40° C. for at least 8 hours, e.g., overnight.
[0074] Solvent Concentration In some embodiments, the concentration of the first solvent used in the process of the present disclosure is 0.1M to 1.5M with respect to "PCO-N-oxide". As an example, the first solvent can be a mixture of water (215mL) and ethanol (1000mL) for the reaction of 112g, 653mmol of "PCO-N-oxide" with 153g (1.3eq) of "Azonia". This results in a 0.5M concentration of PCO-N-oxide with respect to the first solvent. The solvent concentration can be linearly adjusted to accommodate different batch sizes.
[0075] Composition of ORZY-01 In some embodiments, ORZY-01, [ka] And One or more impurities selected from the group consisting of: [ka] A composition comprising:
[0076] In some embodiments, the impurities are present in the provided compositions comprising ORZY-01 at less than about 1% by weight. In some embodiments, an additional recrystallization step can reduce the weight percent of impurities in the provided compositions comprising ORZY-01.
[0077] In some embodiments, (A) is present at 0.1% to 0.5% by weight and / or (B) is present at 0.1% to 0.5% by weight.
[0078] In some embodiments, (A) is present at 0.1 wt% to 0.5 wt%, such as 0.1 wt% to 0.2 wt%, such as 0.2 wt% to 0.3 wt%, such as 0.3 wt% to 0.4 wt%, such as 0.4 wt% to 0.5 wt%.
[0079] In some embodiments, (B) is present at 0.1 wt% to 0.5 wt%, such as 0.1 wt% to 0.2 wt%, such as 0.2 wt% to 0.3 wt%, such as 0.3 wt% to 0.4 wt%, such as 0.4 wt% to 0.5 wt%.
[0080] Step 2 (ORZY-03) As demonstrated by Example 4 of the present disclosure, by using an amount of L-DBTA and a cooling rate of at least 15 K / h for chiral resolution, high chiral and chemical purity is obtained in the production of ORZY-03. The chiral purity of ORZY-03 obtained in step 2 is retained through to the final product ORZY-05 and can be further improved by recrystallization. The improvement of the chiral resolution step, including a cooling rate of at least 15 K / h, allows for the provision of an ultra-pure composition comprising arimoclomol citrate (ORZY-05). In some embodiments, the ultra-pure composition meets the regulatory requirements of drug authorities (e.g., FDA and EMA).
[0081] In some embodiments, a process for preparing ORZY-03 is provided, comprising: [ka] The process comprises the following successive steps: a) ORZY-01, [ka] with dibenzoyl L-tartaric acid (L-DBTA) in a first step 2 solvent in a vessel, heating the first step 2 solvent to a first step 2 temperature, and optionally stirring the first step 2 solvent; b) cooling the first step 2 solvent to a second step 2 temperature at a cooling rate of at least 15 K / h to obtain a solid composition comprising ORZY-03, wherein the first step 2 temperature is higher than the second step 2 temperature; and c) separating the first step 2 solvent from the solid composition comprising ORZY-03, optionally wherein the separation is by filtration; thereby obtaining ORZY-03.
[0082] In some embodiments, the process further comprises the steps of: d) washing the solid composition comprising ORZY-03 one or more times with a first predetermined volume of the first step 2 solvent.
[0083] In some embodiments, the process further comprises the steps of: e) drying the solid composition comprising ORZY-03 under reduced pressure.
[0084] In some embodiments, the process further comprises a step a1) prior to step b), wherein the solvent of the first step 2 is cooled to a temperature of a third step 2, the temperature of the third step 2 being higher than the temperature of the second step 2.
[0085] Step 2: Cooling rate The cooling rate in step 2 results in ORZY-03, an enantiomerically enriched salt. In some embodiments, the use of a cooling rate of 15 K / h or greater increases the chiral purity of ORZY-03.
[0086] In some embodiments, the cooling rate is selected from the group consisting of 15K / h, 16K / h, 17K / h, 18K / h, 19K / h, 20K / h, 21K / h, 22K / h, 23K / h, 24K / h, 25K / h, 26K / h, 27K / h, 28K / h, 29K / h, 30K / h, 31K / h, 32K / h, 33K / h, 34K / h, 35K / h, 36K / h, 37K / h, 38K / h, 39K / h, 40K / h, 41K / h, 42K / h, 43K / h, 44K / h, 45K / h, 46K / h, 47K / h, 48K / h, 49K / h, and 50K / h.
[0087] In some embodiments, the cooling rate is from 15K / h to 50K / h, such as from 15K / h to 16K / h, for example, from 16K / h to 17K / h, for example, from 17K / h to 18K / h, for example, from 18K / h to 19K / h, for example, from 19K / h to 20K / h, for example, from 20K / h to 21K / h, for example, from 21K / h to 22K / h, for example, from 22K / h to 24K / h. K / h to 23K / h, for example, 23K / h to 24K / h, for example, 24K / h to 25K / h, for example, 25K / h to 26K / h, for example, 26K / h to 27K / h, for example, 27K / h to 28K / h, for example, 28K / h to 29K / h, for example, 29K / h to 30K / h, for example, 30K / h to 31K / h, for example, 31K / h to 3 2K / h, for example, 32K / h to 33K / h, for example, 33K / h to 34K / h, for example, 34K / h to 35K / h, for example, 35K / h to 36K / h, for example, 36K / h to 37K / h, for example, 37K / h to 38K / h, for example, 38K / h to 39K / h, for example, 39K / h to 40K / h, for example, 40K / h to 41K / h, For example, 41K / h to 42K / h, for example, 42K / h to 43K / h, for example, 43K / h to 44K / h, for example, 44K / h to 45K / h, for example, 45K / h to 46K / h, for example, 46K / h to 47K / h, for example, 47K / h to 48K / h, for example, 48K / h to 49K / h, or for example, 49K / h to 50K / h.
[0088] In some embodiments, the cooling rate is from 15 K / h to 50 K / h. In some embodiments, the cooling rate is from 15 K / h to 40 K / h. In some embodiments, the cooling rate is from 15 K / h to 30 K / h. In some embodiments, the cooling rate is from 17 K / h to 30 K / h.
[0089] Step 2: Solvent In some embodiments, the first step 2 solvent is a polar protic solvent or a mixture of polar protic solvents.
[0090] In some embodiments, the first step 2 solvent is selected from the group consisting of ethanol, water, methanol, 2-propanol, and any mixture thereof.
[0091] In some embodiments, the first step 2 solvent is a mixture of ethanol and water.
[0092] In some embodiments, the first step 2 solvent is 20.5-23.5 kg water per 55 kg ORZY-01 and 200-240 kg EtOH per 55 kg ORZY-01.
[0093] In some embodiments, the first step 2 solvent is 22 kg water per 55 kg ORZY-01 and 220 kg EtOH per 55 kg ORZY-01.
[0094] Step 2: Temperature In some embodiments, the temperature of the first step 2 is about 60°C to about 75°C, for example, about 61°C to about 74°C, for example, about 62°C to about 73°C, for example, about 63°C to about 72°C, for example, about 64°C to about 71°C, for example, about 65°C to about 70°C, for example, about 65°C.
[0095] In some embodiments, the temperature of the second step 2 is from about 10°C to about 30°C, for example, from about 11°C to about 29°C, for example, from about 12°C to about 28°C, for example, from about 13°C to about 27°C, for example, from about 14°C to about 26°C, for example, from about 15°C to about 25°C, for example, about 20°C.
[0096] In some embodiments, the temperature of the third step 2 is about 45°C to about 65°C, for example, about 46°C to about 64°C, for example, about 47°C to about 63°C, for example, about 48°C to about 62°C, for example, about 49°C to about 61°C, for example, about 50°C to about 60°C, for example, about 51°C to about 59°C, for example, about 52°C to about 58°C, for example, about 53°C to about 57°C, for example, about 54°C to about 56°C, for example, about 55°C.
[0097] Step 2 Method Aspects In some embodiments, the third step 2 temperature is maintained for at least 30 minutes, such as at least 60 minutes.
[0098] In some embodiments, one or more seed crystals of ORZY-03 are added to the vessel prior to step b. In some embodiments, the one or more seed crystals of ORZY-03 have a chiral purity of at least 95%.
[0099] In some embodiments, the mass of the one or more seeds of ORZY-03 is 0.2-0.8 kg per 55 kg of ORZY-03, for example, 0.55 kg per 55 kg of ORZY-03.
[0100] In some embodiments, 0.7 to 1.1 equivalents of L-DBTA, e.g., 0.88 equivalents of L-DBTA, are used per equivalent of ORZY-01 in step 2. In some embodiments, 0.7 to 1.1 equivalents of L-DBTA, e.g., 0.7 to 0.8, e.g., 0.8 to 0.9, e.g., 0.9 to 1.0, e.g., 1.0 to 1.1 equivalents of L-DBTA, are used per equivalent of ORZY-01.
[0101] In some embodiments, the first predetermined volume of the first step 2 solvent is between 35 and 55 kg per 55 kg of ORZY-03. In some embodiments, the first predetermined volume of the first step 2 solvent is between 41 and 45 kg per 55 kg of ORZY-03.
[0102] Step 3 (ORZY-04) As demonstrated by Example 6 of the present disclosure, an optimized step 3, which includes adding a catalytic amount of citric acid prior to the solvent exchange from DCM to MeOH, suppresses the formation of "methoxylated ORZY-04" (referred to herein as impurity RRT 0.74). Example 6 further demonstrates that washing the combined DCM phase with water further reduces the level of impurities such as RRT 0.74. This improvement in step 3 allows for the provision of an ultra-pure composition comprising arimoclomol citrate (ORZY-05). In some embodiments, the ultra-pure composition meets the regulatory requirements of drug authorities (e.g., US or EMA).
[0103] In some embodiments, a process for preparing ORZY-05 is provided, [ka] The process includes the following steps: a) adding a catalytic amount of citric acid to a solution of ORZY-03 in a first Step 3 solvent contained in a vessel; [ka] b) exchanging the solvent of the mixture of step a) from a first step 3 solvent to a second step 3 solvent, said first step 3 solvent being different from said second step 3 solvent; c) adding an approximately stoichiometric amount of citric acid to the mixture obtained in step b) to form a suspension; d) filtering the suspension obtained in step c) to obtain ORZY-04, which is crude ORZY-05; and e) purifying ORZY-04 from step d) to obtain ORZY-05.
[0104] In some embodiments, the process of step 3 further comprises the steps of: f) mixing compound ORZY-03 with a first aqueous solution of step 3 base; and g) extracting the mixture obtained in step a) with the first step 3 solvent to obtain a solution of ORZY-03 in the first step 3 solvent; prior to adding a catalytic amount of citric acid according to step a) to the solution of ORZY-03 in said first step 3 solvent.
[0105] In some embodiments, the process further comprises washing the first step 3 solvent one or more times with water, where one or more by-products are removed from the first step 3 solvent.
[0106] In some embodiments, the process comprises the steps of: a) mixing compound ORZY-03 with an aqueous solution of said first step 3 base; [ka] b) extracting the mixture obtained in step a) with the solvent of the first step 3; c) adding a catalytic amount of citric acid to the organic phase(s) of step b); d) exchanging the solvent of the mixture of step c) from the first step 3 solvent to the second step 3 solvent; e) adding an approximately stoichiometric amount of citric acid to the mixture obtained in step d) to form a suspension; and f) filtering the suspension obtained in step e) to obtain crude ORZY-05 (ORZY-04).
[0107] Step 3: Solvent In some embodiments, the first Step 3 solvent referred to in Step 3 is a chlorinated hydrocarbon or a mixture containing chlorinated hydrocarbons.
[0108] In some embodiments, the first step 3 solvent is dichloromethane or dichloroethane, preferably dichloromethane.
[0109] In some embodiments, the second step 3 solvent is a polar protic solvent or a mixture of polar protic solvents.
[0110] In some embodiments, the second step 3 solvent is selected from the group consisting of methanol, water, ethanol, 2-propanol, and any mixture thereof, hi some embodiments, the second step 3 solvent is methanol.
[0111] Step 3: Bases In some embodiments, the first step 3 base referred to in step 3 is a carbonate. In some embodiments, the first step 3 base is a carbonate selected from the group consisting of K2CO3 and Cs2CO3. In some embodiments, the first step 3 base is K2CO3. In some embodiments, the aqueous solution of K2CO3 comprises 16.8% K2CO3.
[0112] Step 3 Method Aspects In some embodiments, the mixture of ORZY-03 and K2CO3 is extracted three times with CH2Cl2.
[0113] In some embodiments, the solvent exchange from CH2Cl2 to CH3OH comprises the following steps: a. partially distilling the CH2Cl2 solution; b. adding CH3OH to the distilled solution obtained in step a); c. partially distilling the solution obtained in step b); and d. Adding CH3OH to the solution obtained in step c).
[0114] In some embodiments, the amount distilled in steps a) and c) is at least equivalent to the amount of CH2Cl2 in which ORZY-03 was dissolved prior to the solvent exchange step. In some embodiments, the above steps are consecutive steps.
[0115] In some embodiments, the process further comprises passing the solution obtained after solvent exchange from CH2Cl2 to CH3OH through an activated charcoal filter.
[0116] In some embodiments, step 3 further comprises drying the ORZY-04. In some embodiments, the drying step comprises drying the ORZY-04 in vacuum at 45° C. for at least 12 hours.
[0117] In some embodiments, the process comprises the following sequential steps: a) mixing compound ORZY-03 with 16.8% K2CO3 aqueous solution; [ka] b) extracting the mixture obtained in step a) one or more times, e.g., three times, with CH2Cl2, followed by washing the combined organic phase one or more times with water; c) adding a catalytic amount of citric acid to the organic phase(s) of step b); d) changing the solvent of the mixture of step c) from CH2Cl2 to CH3OH; i. partially distilling the CH2Cl2 solution of step c); ii. adding CHOH to the distilled solution obtained in step i); iii. partially distilling the solution obtained in step ii); and iv. Adding CH3OH to the solution obtained in step iii) Step of replacing by e) passing the solution obtained in step d) through an activated carbon filter; f) adding an approximately stoichiometric amount of citric acid to the mixture obtained in step e) to form a suspension; g) filtering the suspension obtained in step e) to obtain ORZY-04; h) drying the ORZY-04 obtained in step g) in vacuum at 45° C. for at least 12 hours; and i) purifying ORZY-04 from step h) to obtain ORZY-05.
[0118] Step 4 (ORZY-05) As demonstrated in Example 7 of the present disclosure, recrystallization under a selected set of conditions results in high chiral and chemical purity of ORZY-05, i.e., arimoclomol citrate salt.
[0119] In some embodiments, the step of purifying ORZY-04 to obtain ORZY-05 described herein comprises recrystallization of ORZY-04. In some embodiments, the solvent used for recrystallization is acetone.
[0120] In some embodiments, the recrystallization comprises the steps of: a. mixing ORZY-04 with HO and heating the mixture to 70±5° C. until a clear solution is observed; b. cooling the solution produced in step a) to 30±5° C.; c. adding acetone to the solution of step b); d. cooling the mixture of step c) to 0±5° C.; e. isolating ORZY-05 from the mixture of step d) by separating the solid and the solvent, and optionally, Drying the ORZY-05 obtained in step f) under vacuum at 45° C. for at least 12 hours.
[0121] In some embodiments, the recrystallization comprises the steps of: a. mixing ORZY-04 with HO and heating the mixture to 70±5° C. until a clear solution is observed; b. cooling the solution produced in step a) to 30±5° C.; c. adding acetone to the solution of step b); d. cooling the mixture of step c) to 0±5° C.; e. stirring the mixture of step d) at 0±10° C. for 12 hours to form a suspension; f. isolating ORZY-05 from the suspension of step e) by filtering the suspension; and Drying the ORZY-05 obtained in step f) under vacuum at 45° C. for at least 12 hours.
[0122] In some embodiments, the cooling from 30°C±5°C to 0°C±5°C is done in 5.5 hours or less, such as 5 hours or less, for example, 4.5 hours or less, such as 4 hours or less, for example, 3.5 hours or less, such as 3 hours or less, for example, 2.5 hours or less, such as 2 hours or less.
[0123] Preparation of Arimoclomol Citrate (ORZY-05) Disclosed herein is an optimized four-step process for preparing an ultra-pure composition comprising arimoclomol citrate, i.e., N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, which comprises multiple optimized sub-steps, each of which contributes to improving the overall process, and allows for the provision of an ultra-pure composition comprising arimoclomol citrate.
[0124] In some embodiments, arimoclomol citrate (ORZY-05) [ka] The present invention provides a process for the preparation of ORZY-05, comprising one or more of the processes described herein for obtaining ORZY-01, ORZY-03, or ORZY-04, thereby obtaining ORZY-05.
[0125] In some embodiments, arimoclomol citrate, [ka] The present invention provides a process for the preparation of ORZY-01, comprising the process defined herein for obtaining ORZY-01, thereby obtaining arimoclomol citrate.
[0126] In some embodiments, a method for preparing arimoclomol citrate comprising the steps of: [ka] The preparation process is provided: a) a process as defined herein for obtaining ORZY-01; [ka] b) precipitating ORZY-01 with dibenzoyl L-tartaric acid to obtain ORZY-03; [ka] and c) reacting ORZY-03 with a base, followed by precipitating the resulting ORZY-03 free base with citric acid to obtain arimoclomol citrate.
[0127] In some embodiments, arimoclomol citrate, [ka] The present invention provides a process for the preparation of a compound comprising the following successive steps: a. obtaining ORZY-01; [ka] b. A process as defined herein for obtaining ORZY-03; [ka] and c. reacting ORZY-03 with a base followed by precipitating the resulting ORZY-03 free base with citric acid to obtain arimoclomol citrate; thereby obtaining arimoclomol citrate.
[0128] In some embodiments, arimoclomol citrate, [ka] The present invention provides a process for the preparation of a compound comprising the following successive steps: a. obtaining ORZY-01; [ka] b. precipitating ORZY-01 with dibenzoyl L-tartaric acid to obtain ORZY-03; [ka] and c. a process as defined herein for obtaining ORZY-05; thereby obtaining arimoclomol citrate.
[0129] Pharmaceutical Compositions In some embodiments, the present disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, having a purity of 98.0% or greater as measured by HPLC.
[0130] In some embodiments, the disclosure provides a composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, having a purity of 98.0% or greater as measured by HPLC.
[0131] In some embodiments, the disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of greater than 98.0% as measured by HPLC.
[0132] In some embodiments, the disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.0% or greater as measured by HPLC.
[0133] In some embodiments, the disclosure provides a pharmaceutical composition, wherein the enantiomeric excess (ee) of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 94%.
[0134] In some embodiments, the disclosure provides a pharmaceutical composition, wherein the ee of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 95%.
[0135] In some embodiments, the disclosure provides a pharmaceutical composition, wherein the ee of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 96%.
[0136] In some embodiments, the disclosure provides a pharmaceutical composition, wherein the ee of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 97%.
[0137] In some embodiments, the disclosure provides a pharmaceutical composition, wherein the ee of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 98%.
[0138] In some embodiments, the disclosure provides a pharmaceutical composition, the composition comprising: a) N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in at least about 94% ee, e.g., at least about 95% ee, e.g., at least about 96% ee, e.g., at least about 97% ee, or e.g., at least about 98% ee, and b) 0.1% or less of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0139] In some embodiments, the disclosure provides a pharmaceutical composition, the composition comprising: a) N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in at least about 94% ee, e.g., at least about 95% ee, e.g., at least about 96% ee, e.g., at least about 97% ee, or e.g., at least about 98% ee; b) 0.1% or less of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; and c) Less than 2 ppm of N-nitrosopiperidine.
[0140] In some embodiments, the disclosure provides a pharmaceutical composition, wherein the purity of the composition is greater than or equal to 99.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate as measured by HPLC.
[0141] In some embodiments, the present disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles having a D10 particle size of about 2.0 μm to about 20.0 μm as measured using a Malvern Mastersizer 3000.
[0142] In some embodiments, the present disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles having a D50 particle size of about 5.0 μm to about 60.0 μm as measured using a Malvern Mastersizer 3000.
[0143] In some embodiments, the present disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles having a D90 particle size of about 30.0 μm to about 130.0 μm as measured using a Malvern Mastersizer 3000.
[0144] In some embodiments, the disclosure provides a pharmaceutical composition, the composition comprising: a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; and c) 0.1% or less of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0145] In some embodiments, the disclosure provides a pharmaceutical composition, the composition comprising: a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; and d) Less than 2 ppm of N-nitrosopiperidine.
[0146] In some embodiments, a pharmaceutical composition comprising ORZY-05, obtainable by the process disclosed herein for preparing ORZY-05, is provided.
[0147] In some embodiments, the disclosure provides a composition, wherein the purity of the composition is 99.0% or greater N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, as measured by HPLC.
[0148] In some embodiments, the present disclosure provides a composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles having a D10 particle size of about 2.0 μm to about 20.0 μm as measured using a Malvern Mastersizer 3000.
[0149] In some embodiments, the present disclosure provides a composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles having a D50 particle size of about 5.0 μm to about 60.0 μm as measured using a Malvern Mastersizer 3000.
[0150] In some embodiments, the present disclosure provides a composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles having a D90 particle size of about 30.0 μm to about 130.0 μm as measured using a Malvern Mastersizer 3000.
[0151] In some embodiments, the disclosure provides a composition comprising: a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; and c) 0.1% or less of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0152] In some embodiments, the disclosure provides a composition comprising: a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; and d) Less than 2 ppm of N-nitrosopiperidine.
[0153] In some embodiments, a composition comprising ORZY-05, obtainable by the process disclosed herein for preparing ORZY-05, is provided.
[0154] In some embodiments, the pharmaceutical composition or composition has a certain purity with respect to N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, which is measured using HPLC.
[0155] In some embodiments, the pharmaceutical composition has a purity of about 98.0%.
[0156] In some embodiments, the pharmaceutical composition has a purity of about 98.25%.
[0157] In some embodiments, the pharmaceutical composition has a purity of about 98.5%.
[0158] In some embodiments, the pharmaceutical composition has a purity of about 98.75%.
[0159] In some embodiments, the pharmaceutical composition has a purity of about 99.0%.
[0160] In some embodiments, the pharmaceutical composition has a purity of about 99.25%.
[0161] In some embodiments, the pharmaceutical composition has a purity of about 99.5%.
[0162] In some embodiments, the pharmaceutical composition has a purity of about 99.6%.
[0163] In some embodiments, the pharmaceutical composition has a purity of about 99.7%.
[0164] In some embodiments, the pharmaceutical composition has a purity of about 99.8%.
[0165] In some embodiments, the pharmaceutical composition has a purity of about 99.9%.
[0166] In some embodiments, the pharmaceutical compositions have a purity of greater than about 99.7%.
[0167] In some embodiments, the pharmaceutical composition contains less than 2% impurities.
[0168] In some embodiments, the pharmaceutical composition contains less than 1.9% impurities.
[0169] In some embodiments, the pharmaceutical composition contains less than 1.8% impurities.
[0170] In some embodiments, the pharmaceutical composition contains less than 1.7% impurities.
[0171] In some embodiments, the pharmaceutical composition contains less than 1.6% impurities.
[0172] In some embodiments, the pharmaceutical composition contains less than 1.5% impurities.
[0173] In some embodiments, the pharmaceutical composition contains less than 1.4% impurities.
[0174] In some embodiments, the pharmaceutical composition contains less than 1.3% impurities.
[0175] In some embodiments, the pharmaceutical composition contains less than 1.2% impurities.
[0176] In some embodiments, the pharmaceutical composition contains less than 1.1% impurities.
[0177] In some embodiments, the pharmaceutical compositions contain less than 1.0% impurities.
[0178] In some embodiments, the pharmaceutical composition contains less than 0.9% impurities.
[0179] In some embodiments, the pharmaceutical composition contains less than 0.8% impurities.
[0180] In some embodiments, the pharmaceutical composition contains less than 0.7% impurities.
[0181] In some embodiments, the pharmaceutical composition contains less than 0.6% impurities.
[0182] In some embodiments, the pharmaceutical compositions contain less than 0.5% impurities.
[0183] In some embodiments, the pharmaceutical compositions contain less than 0.4% impurities.
[0184] In some embodiments, the pharmaceutical compositions contain less than 0.3% impurities.
[0185] In some embodiments, the pharmaceutical compositions contain less than 0.2% impurities.
[0186] In some embodiments, the pharmaceutical compositions contain less than 0.1% impurities.
[0187] In some embodiments, the impurity is a chiral impurity.
[0188] In some embodiments, the impurity is a chemical impurity.
[0189] In some embodiments, the impurity is N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide or a pharma- ceutically acceptable salt thereof.
[0190] In some embodiments, the impurity is methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0191] In some embodiments, the impurity is N-nitrosopiperidine.
[0192] In some embodiments, the impurity is a combination of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma-ceutical acceptable salt thereof, and N-nitrosopiperidine.
[0193] In some embodiments, the impurity is a combination of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma-ceutically acceptable salt thereof.
[0194] In some embodiments, the impurity is a combination of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and N-nitrosopiperidine.
[0195] In some embodiments, the impurity is a combination of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, and N-nitrosopiperidine.
[0196] In some embodiments, N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is chirally pure.
[0197] In some embodiments, N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is chirally pure.
[0198] In some embodiments, chiral purity refers to at least 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0199] In some embodiments, chiral purity refers to up to 2% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0200] In some embodiments, chiral purity refers to a minimum of 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and a maximum of 2% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0201] In some embodiments, chiral purity refers to at least 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0202] In some embodiments, chiral purity refers to up to 1% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0203] In some embodiments, chiral purity refers to a minimum of 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and a maximum of 1% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0204] In some embodiments, chiral purity refers to the inability to detect N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0205] In some embodiments, chiral purity refers to the absence of detectable N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and the absence of detectable other impurities, in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0206] In some embodiments, chiral purity refers to at least 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0207] In some embodiments, chiral purity refers to up to 2% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0208] In some embodiments, chiral purity refers to a minimum of 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and a maximum of 2% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0209] In some embodiments, chiral purity refers to at least 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0210] In some embodiments, chiral purity refers to up to 1% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0211] In some embodiments, chiral purity refers to a minimum of 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and a maximum of 1% N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0212] In some embodiments, chiral purity refers to the absence of detectable N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0213] In some embodiments, chiral purity refers to no detectable N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and no detectable other impurities in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0214] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, is about 94% to about 99% ee.
[0215] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is about 94% to about 99% ee.
[0216] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, is about 94%, about 94.5%, about 95%, about 95.5%, about 96%, about 96.5%, about 97%, about 97.5%, about 98%, about 98.1%, about 98.2%, about 98.3%, about 98.4%, about 98.5%, about 98.6%, about 98.7%, about 98.8%, about 98.9%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, or about 99.9% ee.
[0217] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is about 94%, about 94.5%, about 95%, about 95.5%, about 96%, about 96.5%, about 97%, about 97.5%, about 98%, about 98.1%, about 98.2%, about 98.3%, about 98.4%, about 98.5%, about 98.6%, about 98.7%, about 98.8%, about 98.9%, about 99%, about 99.1%, about 99.2%, about 99.3%, about 99.4%, about 99.5%, about 99.6%, about 99.7%, about 99.8%, or about 99.9% ee.
[0218] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is about 96% ee.
[0219] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is about 96% ee.
[0220] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 94% ee.
[0221] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 95% ee.
[0222] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 96% ee.
[0223] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 97% ee.
[0224] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 98% ee.
[0225] In some embodiments, the enantiomeric excess of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least about 99% ee.
[0226] In some embodiments, N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is chemically pure.
[0227] In some embodiments, N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is chemically pure.
[0228] In some embodiments, chemical purity refers to at least 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0229] In some embodiments, chemical purity refers to at least 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0230] In some embodiments, chemical purity refers to up to 2% methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, or N-nitrosopiperidine.
[0231] In some embodiments, chemical purity refers to a minimum of 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and a maximum of 2% methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma-ceutically acceptable salt thereof, or N-nitrosopiperidine.
[0232] In some embodiments, chemical purity refers to a minimum of 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and a maximum of 2% methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, or N-nitrosopiperidine.
[0233] In some embodiments, chemical purity refers to at least 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0234] In some embodiments, chemical purity refers to at least 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0235] In some embodiments, chiral purity refers to up to 1% methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, or N-nitrosopiperidine.
[0236] In some embodiments, chemical purity refers to a minimum of 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and a maximum of 1% methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma-ceutically acceptable salt thereof, or N-nitrosopiperidine.
[0237] In some embodiments, chemical purity refers to a minimum of 99% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and a maximum of 1% methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, or N-nitrosopiperidine.
[0238] In some embodiments, chemical purity refers to the absence of detectable methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma-ceutically acceptable salt thereof, in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma-ceutically acceptable salt thereof.
[0239] In some embodiments, chemical purity refers to the absence of detectable methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, and the absence of detectable other impurities in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma-ceutically acceptable salt thereof.
[0240] In some embodiments, chemical purity refers to the absence of detectable N-nitrosopiperidine in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide or a pharma- ceutical acceptable salt thereof.
[0241] In some embodiments, chemical purity refers to the absence of detectable N-nitrosopiperidine and no other impurities in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide or a pharma-ceutically acceptable salt thereof.
[0242] In some embodiments, chemical purity refers to the absence of detectable amounts of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, and N-nitrosopiperidine in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0243] In some embodiments, chemical purity refers to the absence of detectable methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, and N-nitrosopiperidine, and the absence of detectable other impurities, in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0244] In some embodiments, chemical purity refers to the absence of detectable methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0245] In some embodiments, chemical purity refers to the absence of detectable methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, and the absence of detectable other impurities in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0246] In some embodiments, chemical purity refers to the absence of detectable N-nitrosopiperidine in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0247] In some embodiments, chemical purity refers to the absence of detectable N-nitrosopiperidine and no other impurities in a composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0248] In some embodiments, the impurities are detected by HPLC.
[0249] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having an enantiomeric excess of about 96% ee, or a pharma- ceutical acceptable salt thereof; b) less than about 0.1% methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; c) less than about 2 ppm N-nitrosopiperidine.
[0250] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate with an enantiomeric excess of about 96% ee; b) less than about 0.1% methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; c) less than about 2 ppm N-nitrosopiperidine.
[0251] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) about 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; b) about 2% of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) less than about 0.1% methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) less than about 2 ppm N-nitrosopiperidine.
[0252] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) about 98% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) about 2% of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) less than about 0.1% methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) less than about 2 ppm N-nitrosopiperidine.
[0253] In some embodiments, the (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, is undetectable.
[0254] In some embodiments, the N-nitrosopiperidine is undetectable.
[0255] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0256] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.2% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0257] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.4% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0258] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.6% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0259] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.8% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0260] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0261] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.2% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0262] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.4% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0263] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.6% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0264] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) 97.0 to 99.8% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, for example 97.2 to 97.4%, for example 97.4 to 97.6%, for example 97.6 to 97.8%, for example 97.8 to 98.0%, for example 98.0 to 98.2%, for example 98.2 to 98.4%, for example 98.4 to 98.6%, for example 98.6 to 98.8%, for example 98.8 to 99.0%, for example 99.0 to 99.2%, for example 99.2 to 99.4%, for example 99.4 to 99.6%, or for example 99.6 to 99.8%, and b) N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0265] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0266] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.1% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.8% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0267] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.2% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.7% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0268] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.3% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.6% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0269] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.4% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.5% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0270] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.5% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.4% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0271] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.6% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.3% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0272] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.7% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.2% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0273] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.8% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.1% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0274] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 98.9% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 1.0% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0275] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0276] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.1% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.8% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0277] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.2% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.7% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0278] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.3% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.6% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0279] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.4% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.5% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0280] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.5% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.4% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0281] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.6% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.3% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0282] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.7% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.2% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0283] In some embodiments, the disclosure provides a pharmaceutical composition comprising: a) at least 99.8% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate; b) 0.1% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; d) Less than 2 ppm of N-nitrosopiperidine.
[0284] formulation In some embodiments, the present disclosure provides an oral formulation comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient.
[0285] In some embodiments, the present disclosure provides an oral formulation comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutically acceptable excipient.
[0286] In some embodiments, the oral formulation comprises a capsule.
[0287] In some embodiments, the oral formulation comprises a bulking agent.
[0288] In some embodiments, the oral formulation comprises a lubricant.
[0289] In some embodiments, the present disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient.
[0290] In some embodiments, the present disclosure provides a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutically acceptable excipient.
[0291] In some embodiments, the pharmaceutical composition comprises a capsule.
[0292] In some embodiments, the pharmaceutical composition comprises a bulking agent.
[0293] In some embodiments, the pharmaceutical composition comprises a lubricant.
[0294] In some embodiments, the capsule comprises a capsule shell.
[0295] In some embodiments, the capsule comprises hydroxypropyl methylcellulose (HPMC), titanium dioxide, and optionally one or more colorants.
[0296] In some embodiments, the capsule shell comprises hydroxypropyl methylcellulose (HPMC), titanium dioxide, and optionally one or more colorants.
[0297] In some embodiments, the bulking agent is microcrystalline cellulose (MCC).
[0298] In some embodiments, the lubricant is magnesium stearate.
[0299] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is present in a dosage of about 20 mg to about 500 mg.
[0300] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide is present in a dosage of about 20 mg to about 500 mg.
[0301] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dosage of about 20 mg to about 500 mg.
[0302] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is present in a dosage of about 50 mg to about 500 mg.
[0303] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide is present in a dosage of about 50 mg to about 500 mg.
[0304] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dosage of about 50 mg to about 500 mg.
[0305] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is present in a dose of about 31 mg, about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0306] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide is present in a dose of about 31 mg, about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0307] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is present in a dose of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0308] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide is present in a dose of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0309] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dose of about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, or about 400 mg.
[0310] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dose of about 75 mg, about 100 mg, about 150 mg, about 200 mg, or about 400 mg.
[0311] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dose of about 50 mg, about 75 mg, about 100 mg, about 150 mg, or about 200 mg.
[0312] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dose of about 75 mg, about 100 mg, about 150 mg, or about 200 mg.
[0313] In some embodiments, the oral formulation comprises about 20% to about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0314] In some embodiments, the oral formulation comprises about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0315] In some embodiments, the oral formulation comprises about 20% to about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0316] In some embodiments, the oral formulation comprises about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0317] In some embodiments, the oral formulation comprises about 26.3% or about 52.6% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0318] In some embodiments, the oral formulation comprises about 40% to about 80% w / w microcrystalline cellulose.
[0319] In some embodiments, the oral formulation comprises about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80% w / w microcrystalline cellulose.
[0320] In some embodiments, the oral formulation comprises about 73.2% or about 46.9% w / w microcrystalline cellulose.
[0321] In some embodiments, the oral formulation contains from about 0.0% to about 1.0% magnesium stearate.
[0322] In some embodiments, the oral formulation comprises about 0.0%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 1.0% magnesium stearate.
[0323] In some embodiments, the oral formulation comprises about 0.5% magnesium stearate.
[0324] In some embodiments, the pharmaceutical composition comprises about 20% to about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof.
[0325] In some embodiments, the pharmaceutical composition comprises about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof.
[0326] In some embodiments, the pharmaceutical composition comprises about 20% to about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0327] In some embodiments, the pharmaceutical composition comprises about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0328] In some embodiments, the pharmaceutical composition comprises about 26.3% or about 52.6% w / w N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0329] In some embodiments, the pharmaceutical compositions comprise about 40% to about 80% w / w microcrystalline cellulose.
[0330] In some embodiments, the pharmaceutical compositions comprise about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, or about 80% w / w microcrystalline cellulose.
[0331] In some embodiments, the pharmaceutical composition comprises about 73.2% or about 46.9% w / w microcrystalline cellulose.
[0332] In some embodiments, the pharmaceutical compositions comprise about 0.0% to about 1.0% w / w magnesium stearate.
[0333] In some embodiments, the pharmaceutical compositions comprise about 0.0%, about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, or about 1.0% magnesium stearate.
[0334] In some embodiments, the pharmaceutical composition comprises about 0.5% w / w magnesium stearate.
[0335] In some embodiments, the disclosure provides a unit dosage form of a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier or excipient.
[0336] In some embodiments, the disclosure provides a unit dosage form of a pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and a pharma- ceutically acceptable carrier or excipient.
[0337] In some embodiments, the present disclosure provides an oral formulation comprising a unit dose of the present disclosure and a pharma- ceutically acceptable carrier or excipient.
[0338] In some embodiments, the unit dosage form comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 50 mg to about 500 mg.
[0339] In some embodiments, the unit dosage form comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide in a dosage of about 50 mg to about 500 mg.
[0340] In some embodiments, the unit dosage form comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dosage of about 20 mg to about 500 mg.
[0341] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 20 mg to about 500 mg.
[0342] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide in a dosage of about 20 mg to about 500 mg.
[0343] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dosage of about 20 mg to about 500 mg.
[0344] In some embodiments, the unit dosage form comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dosage of about 50 mg to about 500 mg.
[0345] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 50 mg to about 500 mg.
[0346] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide in a dosage of about 50 mg to about 500 mg.
[0347] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dosage of about 50 mg to about 500 mg.
[0348] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 31 mg, about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0349] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide in a dose of about 31 mg, about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0350] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0351] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide in a dose of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0352] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dose of about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, or about 400 mg.
[0353] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dose of about 50 mg, about 75 mg, about 100 mg, about 150 mg, or about 200 mg.
[0354] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dose of about 75 mg, about 100 mg, about 150 mg, about 200 mg, or about 400 mg.
[0355] In some embodiments, the oral formulation comprises a unit dosage form comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dose of about 75 mg, about 100 mg, about 150 mg, or about 200 mg.
[0356] In some embodiments, the disclosure provides a kit comprising a unit dosage form and instructions for administration.
[0357] In some embodiments, the kit further comprises prescribing information and / or a number of unit dosages.
[0358] In some embodiments of the oral formulation, the capsule is blue, green, yellow, orange, or red.
[0359] In some embodiments of the pharmaceutical composition, the capsule is blue, green, yellow, orange, or red.
[0360] In some embodiments of the unit dose, the capsule is blue, green, yellow, orange, or red.
[0361] In some embodiments of the oral formulation, the capsule has a white body.
[0362] In some embodiments of the pharmaceutical composition, the capsule has a white body.
[0363] In some embodiments of the unit dose, the capsule has a white body.
[0364] In some embodiments of the oral formulation, the capsule is size "0."
[0365] In some embodiments of the pharmaceutical composition, the capsule is size "0."
[0366] In some embodiments of the unit dose, the capsule is size "0."
[0367] In some embodiments, the capsule contains a dose of about 31 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, or about 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0368] In some embodiments, the capsule contains a dose of about 50 mg, about 75 mg, about 100, about 150 mg, or about 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0369] In some embodiments, the capsule contains about a 50 mg, about 75 mg, or about 100 mg dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0370] In some embodiments, the capsules are filled with a low powder blend of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0371] In some embodiments, the low powder blend comprises 100 mg of a powder blend in which N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present at about 26.2% w / w.
[0372] In some embodiments, capsules containing about 50 mg, about 75 mg, or about 100 mg doses of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate are filled with the low powder blend.
[0373] In some embodiments, the capsule contains a dose of about 150 mg or about 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0374] In some embodiments, the capsules are filled with a high powder blend of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0375] In some embodiments, the high powder blend comprises 200 mg of a powder blend in which N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present at about 52.6% w / w.
[0376] In some embodiments, capsules containing about a 150 mg or about 200 mg dose of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate are filled with the high powder blend.
[0377] In some embodiments, the oral formulation comprises ultra-pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate. In some embodiments, the pharmaceutical composition comprises ultra-pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0378] In some embodiments, the unit dose comprises ultra-pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0379] In some embodiments, the purity is measured by HPLC.
[0380] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0381] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0382] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0383] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 98.0% or greater.
[0384] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 98.0% or greater.
[0385] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 98.0% or greater.
[0386] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0387] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0388] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0389] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 98.5% or greater.
[0390] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 98.5% or greater.
[0391] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 98.5% or greater.
[0392] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0393] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0394] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0395] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.0% or greater.
[0396] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.0% or greater.
[0397] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.0% or greater.
[0398] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.25% or greater, or a pharma- ceutically acceptable salt thereof.
[0399] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.25% or greater, or a pharma- ceutically acceptable salt thereof.
[0400] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.25% or greater, or a pharma- ceutically acceptable salt thereof.
[0401] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.25% or greater.
[0402] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.25% or greater.
[0403] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.25% or greater.
[0404] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0405] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.5% or greater, or a pharma- ceutical acceptable salt thereof.
[0406] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0407] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.5% or greater.
[0408] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.5% or greater.
[0409] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.5% or greater.
[0410] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.6% or greater, or a pharma- ceutically acceptable salt thereof.
[0411] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.6% or greater, or a pharma- ceutical acceptable salt thereof.
[0412] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.6% or greater, or a pharma- ceutically acceptable salt thereof.
[0413] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.6% or greater.
[0414] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.6% or greater.
[0415] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.6% or greater.
[0416] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.7% or greater, or a pharma- ceutically acceptable salt thereof.
[0417] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.7% or greater, or a pharma- ceutically acceptable salt thereof.
[0418] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.7% or greater, or a pharma- ceutically acceptable salt thereof.
[0419] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.7% or greater.
[0420] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.7% or greater.
[0421] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.7% or greater.
[0422] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.8% or greater, or a pharma- ceutically acceptable salt thereof.
[0423] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.8% or greater, or a pharma- ceutical acceptable salt thereof.
[0424] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a purity of 99.8% or greater, or a pharma- ceutically acceptable salt thereof. In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.8% or greater.
[0425] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.8% or greater.
[0426] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a purity of 99.8% or greater.
[0427] In some embodiments, the oral formulation comprises chirally pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0428] In some embodiments, the pharmaceutical composition comprises chirally pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0429] In some embodiments, the unit dose comprises chirally pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0430] In some embodiments, the oral formulation comprises chirally pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0431] In some embodiments, the pharmaceutical composition comprises chirally pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0432] In some embodiments, the unit dose comprises chirally pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0433] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0434] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 98.0% or greater, or a pharma- ceutical acceptable salt thereof.
[0435] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0436] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 98.0% or greater.
[0437] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 98.0% or greater.
[0438] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 98.0% or greater.
[0439] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0440] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 98.5% or greater, or a pharma- ceutical acceptable salt thereof.
[0441] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0442] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 98.5% or greater.
[0443] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 98.5% or greater.
[0444] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 98.5% or greater.
[0445] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0446] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 99.0% or greater, or a pharma- ceutical acceptable salt thereof.
[0447] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chiral purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0448] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 99.0% or greater.
[0449] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 99.0% or greater.
[0450] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chiral purity of 99.0% or greater.
[0451] In some embodiments, the oral formulation comprises chemically pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0452] In some embodiments, the pharmaceutical composition comprises chemically pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0453] In some embodiments, the unit dose comprises chemically pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0454] In some embodiments, the oral formulation comprises chemically pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0455] In some embodiments, the pharmaceutical composition comprises chemically pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0456] In some embodiments, the unit dose comprises chemically pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0457] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0458] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0459] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 98.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0460] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 98.0% or greater.
[0461] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 98.0% or greater.
[0462] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 98.0% or greater.
[0463] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0464] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0465] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 98.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0466] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 98.5% or greater.
[0467] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 98.5% or greater.
[0468] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 98.5% or greater.
[0469] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0470] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0471] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.0% or greater, or a pharma- ceutically acceptable salt thereof.
[0472] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.0% or greater.
[0473] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.0% or greater.
[0474] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.0% or greater.
[0475] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.25% or greater, or a pharma- ceutically acceptable salt thereof.
[0476] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.25% or greater, or a pharma- ceutically acceptable salt thereof.
[0477] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.25% or greater, or a pharma- ceutically acceptable salt thereof.
[0478] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.25% or greater.
[0479] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.25% or greater.
[0480] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.25% or greater.
[0481] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0482] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0483] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.5% or greater, or a pharma- ceutically acceptable salt thereof.
[0484] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.5% or greater.
[0485] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.5% or greater.
[0486] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.5% or greater.
[0487] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.6% or greater, or a pharma- ceutically acceptable salt thereof.
[0488] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.6% or greater, or a pharma- ceutically acceptable salt thereof.
[0489] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.6% or greater, or a pharma- ceutically acceptable salt thereof.
[0490] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.6% or greater.
[0491] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.6% or greater.
[0492] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.6% or greater.
[0493] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.7% or greater, or a pharma- ceutically acceptable salt thereof.
[0494] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.7% or greater, or a pharma- ceutically acceptable salt thereof.
[0495] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.7% or greater, or a pharma- ceutically acceptable salt thereof.
[0496] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.7% or greater.
[0497] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.7% or greater.
[0498] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.7% or greater.
[0499] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.8% or greater, or a pharma- ceutically acceptable salt thereof.
[0500] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.8% or greater, or a pharma- ceutically acceptable salt thereof.
[0501] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.8% or greater, or a pharma- ceutically acceptable salt thereof.
[0502] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.8% or greater.
[0503] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.8% or greater.
[0504] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.8% or greater.
[0505] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.9% or greater, or a pharma- ceutically acceptable salt thereof.
[0506] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.9% or greater, or a pharma- ceutically acceptable salt thereof.
[0507] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide having a chemical purity of 99.9% or greater, or a pharma- ceutically acceptable salt thereof.
[0508] In some embodiments, the oral formulation comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.9% or greater.
[0509] In some embodiments, the pharmaceutical composition comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.9% or greater.
[0510] In some embodiments, the unit dose comprises N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate having a chemical purity of 99.9% or greater.
[0511] In some embodiments, the oral formulation contains less than 2 ppm of impurities.
[0512] In some embodiments, the pharmaceutical composition contains less than 2 ppm of impurities.
[0513] In some embodiments, the unit dose contains less than 2 ppm of impurities.
[0514] In some embodiments, the oral formulation contains less than 1 ppm of impurities.
[0515] In some embodiments, the pharmaceutical composition contains less than 1 ppm of impurities.
[0516] In some embodiments, the unit dose contains less than 1 ppm of impurities.
[0517] In some embodiments, the oral formulation is free of detectable impurities.
[0518] In some embodiments, the pharmaceutical compositions are free of detectable impurities.
[0519] In some embodiments, the unit dose is free of detectable impurities.
[0520] In some embodiments, the impurity is N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide or a pharma- ceutically acceptable salt thereof.
[0521] In some embodiments, the impurity is methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0522] In some embodiments, the oral formulation contains less than about 0.1% (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0523] In some embodiments, the pharmaceutical composition comprises less than about 0.1% of (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0524] In some embodiments, the unit dose comprises less than about 0.1% of (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0525] In some embodiments, the oral formulation contains less than about 0.05% (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0526] In some embodiments, the pharmaceutical composition comprises less than about 0.05% of (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0527] In some embodiments, the unit dose comprises less than about 0.05% (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0528] In some embodiments, the oral formulation contains no detectable (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0529] In some embodiments, the pharmaceutical composition does not include (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0530] In some embodiments, the unit dose contains no detectable (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof.
[0531] In some embodiments, the impurity is N-nitrosopiperidine.
[0532] In some embodiments, the oral formulation contains less than about 2 ppm of N-nitrosopiperidine.
[0533] In some embodiments, the pharmaceutical composition comprises less than about 2 ppm of N-nitrosopiperidine.
[0534] In some embodiments, the unit dose contains less than about 2 ppm of N-nitrosopiperidine.
[0535] In some embodiments, the oral formulation contains less than about 1.6 ppm of N-nitrosopiperidine.
[0536] In some embodiments, the pharmaceutical compositions contain less than about 1.6 ppm of N-nitrosopiperidine.
[0537] In some embodiments, the unit dose contains less than about 1.6 ppm of N-nitrosopiperidine.
[0538] In some embodiments, the oral formulation contains less than about 1 ppm of N-nitrosopiperidine.
[0539] In some embodiments, the pharmaceutical composition comprises less than about 1 ppm of N-nitrosopiperidine.
[0540] In some embodiments, the unit dose contains less than about 1 ppm of N-nitrosopiperidine.
[0541] In some embodiments, the oral formulation contains less than about 0.8 ppm of N-nitrosopiperidine.
[0542] In some embodiments, the pharmaceutical compositions contain less than about 0.8 ppm of N-nitrosopiperidine.
[0543] In some embodiments, the unit dose contains less than about 0.8 ppm of N-nitrosopiperidine.
[0544] In some embodiments, the oral formulation contains no detectable N-nitrosopiperidine.
[0545] In some embodiments, the pharmaceutical composition does not include N-nitrosopiperidine.
[0546] In some embodiments, the unit dose contains no detectable N-nitrosopiperidine.
[0547] In some embodiments, the impurity is N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide or a pharma- ceutically acceptable salt thereof, methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof, or a combination of N-nitrosopiperidine, and combinations thereof.
[0548] In some embodiments, the impurity is a combination of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma-ceutically acceptable salt thereof.
[0549] In some embodiments, the impurity is a combination of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and N-nitrosopiperidine.
[0550] In some embodiments, the impurity is a combination of methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof, and N-nitrosopiperidine.
[0551] In some embodiments, the pharma- ceutically acceptable salt is N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0552] medical use In some embodiments, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the oral formulation comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient.
[0553] In some embodiments, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma- ceutical acceptable excipient.
[0554] In some embodiments, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of said unit dose comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient.
[0555] In some embodiments, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the oral formulation comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and at least one pharma- ceutical acceptable excipient.
[0556] In some embodiments, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and at least one pharma- ceutical acceptable excipient.
[0557] In some embodiments, the disclosure provides a method of treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of the unit dose comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and at least one pharma- ceutical acceptable excipient.
[0558] In some embodiments, the disclosure provides an oral formulation of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0559] In some embodiments, the disclosure provides a pharmaceutical composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0560] In some embodiments, the disclosure provides a unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0561] In some embodiments, the disclosure provides an oral formulation of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutical acceptable excipient for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0562] In some embodiments, the disclosure provides a pharmaceutical composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutical acceptable excipient for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0563] In some embodiments, the disclosure provides a unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutical acceptable excipient for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0564] In some embodiments, the disclosure provides use of an oral formulation of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0565] In some embodiments, the disclosure provides use of a pharmaceutical composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0566] In some embodiments, the disclosure provides use of a unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0567] In some embodiments, the disclosure provides use of an oral formulation of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and at least one pharma- ceutical acceptable excipient, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0568] In some embodiments, the disclosure provides use of a pharmaceutical composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and at least one pharma- ceutical acceptable excipient, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0569] In some embodiments, the disclosure provides use of a unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and at least one pharma- ceutical acceptable excipient, for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0570] In some embodiments, the disclosure provides use of an oral formulation of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0571] In some embodiments, the disclosure provides use of a pharmaceutical composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0572] In some embodiments, the disclosure provides use of a unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutical acceptable salt thereof, and at least one pharma-ceutical acceptable excipient, for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0573] In some embodiments, the disclosure provides use of an oral formulation of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutical acceptable excipient for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0574] In some embodiments, the disclosure provides use of a pharmaceutical composition of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutical acceptable excipient for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0575] In some embodiments, the disclosure provides use of a unit dose of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate and at least one pharma- ceutical acceptable excipient for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0576] In some embodiments, the oral formulation is administered once, twice, three times, or four times daily.
[0577] In some embodiments, the pharmaceutical compositions are administered once, twice, three times, or four times daily.
[0578] In some embodiments, the unit dose is administered once, twice, three times, or four times daily.
[0579] In some embodiments, the oral formulation is administered three times daily.
[0580] In some embodiments, the pharmaceutical composition is administered three times daily.
[0581] In some embodiments, the unit dose is administered three times daily.
[0582] In some embodiments, the oral formulation is administered three times daily for six consecutive days.
[0583] In some embodiments, the pharmaceutical composition is administered three times daily for six consecutive days.
[0584] In some embodiments, the unit dose is administered three times a day for six consecutive days.
[0585] In some embodiments, the oral formulation is administered under fasting conditions.
[0586] In some embodiments, the pharmaceutical composition is administered under fasting conditions.
[0587] In some embodiments, the unit dose is administered under fasting conditions.
[0588] In some embodiments, the oral formulation is administered as a single dose in the morning.
[0589] In some embodiments, the pharmaceutical composition is administered as a single dose in the morning.
[0590] In some embodiments, the unit dose is administered as a single dose in the morning.
[0591] In some embodiments, the oral formulation is administered to a subject weighing about 70 kg.
[0592] In some embodiments, the pharmaceutical composition is administered to a subject weighing about 70 kg.
[0593] In some embodiments, the unit dose is administered to a subject weighing about 70 kg.
[0594] In some embodiments, the subject is a human.
[0595] In some embodiments, the human is an adult. In some embodiments, the human is a pediatric patient (e.g., 2 years of age or older).
[0596] In some embodiments, the oral formulation is administered as set forth in Table A.
[0597] In some embodiments, the pharmaceutical compositions are administered as described in Table A.
[0598] In some embodiments, the unit dose is administered as set forth in Table A.
[0599] In some embodiments, the oral formulation is administered as set forth in Table B.
[0600] In some embodiments, the pharmaceutical compositions are administered as described in Table B.
[0601] In some embodiments, the unit dose is administered as set forth in Table B. [Table 1] [Table 2]
[0602] In some embodiments, the oral formulation is administered to a pediatric subject weighing between about 8 kg and about 15 kg.
[0603] In some embodiments, the pharmaceutical composition is administered to a pediatric subject weighing between about 8 kg and about 15 kg.
[0604] In some embodiments, the unit dose is administered to a pediatric subject weighing between about 8 kg and about 15 kg.
[0605] In some embodiments, the oral formulation is administered to a pediatric subject weighing between about 15 kg and about 22 kg.
[0606] In some embodiments, the pharmaceutical composition is administered to a pediatric subject weighing between about 15 kg and about 22 kg.
[0607] In some embodiments, the unit dose is administered to a pediatric subject weighing between about 15 kg and about 22 kg.
[0608] In some embodiments, the oral formulation is administered at a dose of about 31 mg.
[0609] In some embodiments, the pharmaceutical composition is administered at a dose of about 31 mg.
[0610] In some embodiments, the unit dose is administered in a dose of about 31 mg.
[0611] In some embodiments, the oral formulation is administered at a dose of about 50 mg.
[0612] In some embodiments, the pharmaceutical composition is administered at a dose of about 50 mg.
[0613] In some embodiments, the unit dose is administered in a dose of about 50 mg.
[0614] In some embodiments, the oral formulation is administered at a dose of about 47 mg.
[0615] In some embodiments, the pharmaceutical composition is administered at a dose of about 47 mg.
[0616] In some embodiments, the unit dose is administered in a dose of about 47 mg.
[0617] In some embodiments, the oral formulation is administered at a dose of about 75 mg.
[0618] In some embodiments, the pharmaceutical composition is administered at a dose of about 75 mg.
[0619] In some embodiments, the unit dose is administered in a dose of about 75 mg.
[0620] In some embodiments, the oral formulation is administered to a subject weighing about 15 kg to about 30 kg.
[0621] In some embodiments, the pharmaceutical composition is administered to a subject weighing about 15 kg to about 30 kg.
[0622] In some embodiments, the unit dose is administered to a subject weighing about 15 kg to about 30 kg.
[0623] In some embodiments, the oral formulation is administered to a subject weighing between about 22 kg and about 38 kg.
[0624] In some embodiments, the pharmaceutical composition is administered to a subject weighing between about 22 kg and about 38 kg.
[0625] In some embodiments, the unit dose is administered to a subject weighing between about 22 kg and about 38 kg.
[0626] In some embodiments, the oral formulation is administered at a dose of about 62 mg. In some embodiments, the pharmaceutical composition is administered at a dose of about 62 mg. In some embodiments, the unit dose is administered at a dose of about 62 mg.
[0627] In some embodiments, the oral formulation is administered at a dose of about 100 mg.
[0628] In some embodiments, the pharmaceutical composition is administered at a dose of about 100 mg.
[0629] In some embodiments, the unit dose is administered in a dose of about 100 mg.
[0630] In some embodiments, the oral formulation is administered to a subject weighing about 30 kg to about 55 kg. In some embodiments, the pharmaceutical composition is administered to a subject weighing about 30 kg to about 55 kg.
[0631] In some embodiments, the unit dose is administered to a subject weighing between about 30 kg and about 55 kg.
[0632] In some embodiments, the oral formulation is administered to a subject weighing about 38 kg to about 55 kg.
[0633] In some embodiments, the pharmaceutical composition is administered to a subject weighing between about 38 kg and about 55 kg.
[0634] In some embodiments, the unit dose is administered to a subject weighing between about 38 kg and about 55 kg.
[0635] In some embodiments, the oral formulation is administered at a dose of about 93 mg.
[0636] In some embodiments, the pharmaceutical composition is administered at a dose of about 93 mg.
[0637] In some embodiments, the unit dose is administered in a dose of about 93 mg.
[0638] In some embodiments, the oral formulation is administered at a dose of about 150 mg.
[0639] In some embodiments, the pharmaceutical composition is administered at a dose of about 150 mg.
[0640] In some embodiments, the unit dose is administered in a dose of about 150 mg.
[0641] In some embodiments, the oral formulation is administered to a subject having a body weight greater than about 55 kg.
[0642] In some embodiments, the pharmaceutical composition is administered to a subject having a body weight greater than about 55 kg.
[0643] In some embodiments, the unit dose is administered to a subject having a body weight greater than about 55 kg.
[0644] In some embodiments, the oral formulation is administered at a dose of about 124 mg.
[0645] In some embodiments, the pharmaceutical composition is administered at a dose of about 124 mg.
[0646] In some embodiments, the unit dose is administered in a dose of about 124 mg.
[0647] In some embodiments, the oral formulation is administered at a dose of about 200 mg.
[0648] In some embodiments, the pharmaceutical composition is administered at a dose of about 200 mg.
[0649] In some embodiments, the unit dose is administered in a dose of about 200 mg.
[0650] In some embodiments, at least about 85% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, dissolves in solution in about 15 minutes.
[0651] In some embodiments, at least 85% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, dissolves in a solution at a pH of about 1.2, about 4.5, or about 6.8 in about 15 minutes.
[0652] In some embodiments, at least about 85% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate dissolves in the solution in about 15 minutes.
[0653] In some embodiments, at least 85% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate dissolves in a solution at a pH of about 1.2, about 4.5, or about 6.8 in about 15 minutes.
[0654] In some embodiments, at least about 80% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, dissolves in solution in about 30 minutes.
[0655] In some embodiments, at least 80% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, dissolves in a solution at a pH of about 1.2, about 4.5, or about 6.8 in about 30 minutes.
[0656] In some embodiments, at least about 80% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate dissolves in the solution in about 30 minutes.
[0657] In some embodiments, at least 80% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate dissolves in a solution at a pH of about 1.2, about 4.5, or about 6.8 in about 30 minutes.
[0658] In some embodiments, the capsule ingredients are mixed with a liquid for oral administration as a liquid.
[0659] In some embodiments, the liquid is 20 mL or less. In some embodiments, the liquid is 15 mL or less.
[0660] In some embodiments, the liquid is water, hi some embodiments, the liquid is apple juice.
[0661] In some embodiments, the capsule ingredients are mixed with soft food for oral administration.
[0662] In some embodiments, the present disclosure provides an oral formulation comprising: Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and Approximately 0.95 mg of magnesium stearate.
[0663] In some embodiments, the disclosure provides a pharmaceutical composition comprising: Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and Approximately 0.95 mg of magnesium stearate.
[0664] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 0.95 mg of magnesium stearate; The subject weighs from about 8 kg to about 15 kg.
[0665] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 0.95 mg of magnesium stearate; The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0666] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and providing an oral formulation comprising about 0.95 mg of magnesium stearate; The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0667] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 0.95 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0668] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 0.95 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0669] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 0.95 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0670] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 0.95 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0671] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 50 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 139.05 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 0.95 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0672] In some embodiments, the present disclosure provides an oral formulation comprising: Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and Approximately 1.43 mg of magnesium stearate.
[0673] In some embodiments, the disclosure provides a pharmaceutical composition comprising: Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and Approximately 1.43 mg of magnesium stearate.
[0674] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.43 mg of magnesium stearate; The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0675] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.43 mg of magnesium stearate; The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0676] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0677] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0678] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0679] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0680] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0681] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject is a pediatric subject weighing from about 8 kg to about 15 kg.
[0682] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.43 mg of magnesium stearate; The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0683] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.43 mg of magnesium stearate; The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0684] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0685] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0686] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0687] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0688] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0689] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 75 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 208.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject is a pediatric subject weighing from about 15 kg to about 22 kg.
[0690] In some embodiments, the present disclosure provides an oral formulation comprising: Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and Approximately 1.90 mg of magnesium stearate.
[0691] In some embodiments, the disclosure provides a pharmaceutical composition comprising: Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and Approximately 1.90 mg of magnesium stearate.
[0692] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.90 mg of magnesium stearate; The subject has a body weight of greater than about 15 kg to about 30 kg.
[0693] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.90 mg of magnesium stearate; The subject has a body weight of greater than about 15 kg to about 30 kg.
[0694] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.90 mg of magnesium stearate; The subject has a body weight of greater than about 15 kg to about 30 kg.
[0695] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 15 kg to about 30 kg.
[0696] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides for the use of an oral formulation comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 15 kg to about 30 kg.
[0697] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 15 kg to about 30 kg.
[0698] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides for the use of an oral formulation comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 15 kg to about 30 kg.
[0699] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 15 kg to about 30 kg.
[0700] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.90 mg of magnesium stearate; The subject has a body weight of greater than about 22 kg to about 38 kg.
[0701] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.90 mg of magnesium stearate; The subject has a body weight of greater than about 22 kg to about 38 kg.
[0702] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.90 mg of magnesium stearate; The subject has a body weight of greater than about 22 kg to about 38 kg.
[0703] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 22 kg to about 38 kg.
[0704] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides for the use of an oral formulation comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 22 kg to about 38 kg.
[0705] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 22 kg to about 38 kg.
[0706] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides for the use of an oral formulation comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 22 kg to about 38 kg.
[0707] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 100 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 278.1 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 1.90 mg of magnesium stearate, The subject has a body weight of greater than about 22 kg to about 38 kg.
[0708] In some embodiments, the present disclosure provides an oral formulation comprising: Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and Approximately 1.43 mg of magnesium stearate.
[0709] In some embodiments, the disclosure provides a pharmaceutical composition comprising: Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and Approximately 1.43 mg of magnesium stearate.
[0710] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.43 mg of magnesium stearate; The subject has a body weight of greater than about 30 kg to about 55 kg.
[0711] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.43 mg of magnesium stearate; The subject has a body weight of greater than about 30 kg to about 55 kg.
[0712] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 30 kg to about 55 kg.
[0713] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 30 kg to about 55 kg.
[0714] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 30 kg to about 55 kg.
[0715] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject has a body weight of greater than about 30 kg to about 55 kg.
[0716] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 30 kg to about 55 kg.
[0717] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject has a body weight of greater than about 30 kg to about 55 kg.
[0718] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.43 mg of magnesium stearate; The subject has a body weight of greater than about 38 kg to about 55 kg.
[0719] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.43 mg of magnesium stearate; The subject has a body weight of greater than about 38 kg to about 55 kg.
[0720] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 38 kg to about 55 kg.
[0721] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 38 kg to about 55 kg.
[0722] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 38 kg to about 55 kg.
[0723] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject has a body weight of greater than about 38 kg to about 55 kg.
[0724] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.43 mg of magnesium stearate, The subject has a body weight of greater than about 38 kg to about 55 kg.
[0725] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 150 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, approximately 133.57 mg microcrystalline cellulose, and The present invention provides a method for treating a patient suffering from a chronic inflammatory bowel disease, comprising administering to said patient a therapeutically effective amount of magnesium stearate in a patient receiving said treatment. The subject has a body weight of greater than about 38 kg to about 55 kg.
[0726] In some embodiments, the present disclosure provides an oral formulation comprising: Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and Approximately 1.9 mg of magnesium stearate.
[0727] In some embodiments, the disclosure provides a pharmaceutical composition comprising: Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and Approximately 1.9 mg of magnesium stearate.
[0728] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and administering a therapeutically effective amount of the oral formulation comprising about 1.9 mg of magnesium stearate; The subject has a body weight greater than about 55 kg.
[0729] In some embodiments, the disclosure provides a method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, comprising: Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and administering a therapeutically effective amount of the pharmaceutical composition comprising about 1.9 mg of magnesium stearate; The subject has a body weight greater than about 55 kg.
[0730] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and providing an oral formulation comprising about 1.9 mg of magnesium stearate; The subject has a body weight greater than about 55 kg.
[0731] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound selected from the group consisting of phenylephrine, ... Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and providing a pharmaceutical composition comprising about 1.9 mg of magnesium stearate, The subject has a body weight greater than about 55 kg.
[0732] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.9 mg of magnesium stearate, The subject has a body weight greater than about 55 kg.
[0733] In some embodiments, the disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a compound of formula (I) or (II) of the present invention thereto. Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 1.9 mg of magnesium stearate, The subject has a body weight greater than about 55 kg.
[0734] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and providing use of an oral formulation comprising about 1.9 mg of magnesium stearate, The subject has a body weight greater than about 55 kg.
[0735] In some embodiments, the present disclosure provides a method for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of Approximately 200 mg of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, about 178.1 mg microcrystalline cellulose, and The present invention provides a pharmaceutical composition comprising about 1.9 mg of magnesium stearate, The subject has a body weight greater than about 55 kg.
[0736] In some embodiments, the oral formulation comprises a capsule.
[0737] In some embodiments, the pharmaceutical composition comprises a capsule.
[0738] In some embodiments, the geometric mean C max is measured relative to a 70 kg man.
[0739] In some embodiments, the geometric mean C of the oral formulation after a single dose is max is C max This is within approximately 80.00% to approximately 125.00% of 1749 (CV 49%) ng / mL.
[0740] In some embodiments, the geometric mean C of the pharmaceutical composition after a single dose is max is C max This is within approximately 80.00% to approximately 125.00% of 1749 (CV 49%) ng / mL.
[0741] In some embodiments, the geometric mean C of the unit dose after a single administration max is C max This is within approximately 80.00% to approximately 125.00% of 1749 (CV 49%) ng / mL.
[0742] In some embodiments, the AUC 0-8時間 is the AUC 0-8時間 5317 (CV 17%), within approximately 80.00% to approximately 125.00% of h·ng / mL.
[0743] In some embodiments, the AUC of the pharmaceutical composition after a single administration 0-8時間 is the AUC 0-8時間 5317 (CV 17%), within approximately 80.00% to approximately 125.00% of h·ng / mL.
[0744] In some embodiments, the AUC of the unit dose after a single administration 0-8時間 is the AUC 0-8時間 5317 (CV 17%), within approximately 80.00% to approximately 125.00% of h·ng / mL.
[0745] In some embodiments, the AUC 0-無限大 is the AUC 0-無限大 6331 (CV 17%) is within approximately 80.00% to approximately 125.00% of h ng / mL.
[0746] In some embodiments, the AUC of the pharmaceutical composition after a single administration 0-無限大 is the AUC 0-無限大 6331 (CV 17%) is within approximately 80.00% to approximately 125.00% of h ng / mL.
[0747] In some embodiments, the AUC of the oral dose after a single administration 0-無限大 is the AUC 0-無限大 6331 (CV 17%) is within approximately 80.00% to approximately 125.00% of h ng / mL.
[0748] In some embodiments, the steady-state geometric mean C of the oral formulation after administration max,定常状態 is C max,定常状態 This is within approximately 80.00% to approximately 125.00% of 2090 (CV 23%) ng / mL.
[0749] In some embodiments, the steady state geometric mean C of the pharmaceutical composition after administration max,定常状態 is C max,定常状態 This is within approximately 80.00% to approximately 125.00% of 2090 (CV 23%) ng / mL.
[0750] In some embodiments, the geometric mean C of the unit dose at steady state after administration max,定常状態 is C max,定常状態 This is within approximately 80.00% to approximately 125.00% of 2090 (CV 23%) ng / mL.
[0751] In some embodiments, the AUC 0-8時間,定常状態 is the AUC 0-8時間,定常状態 7207 (CV 19%), within approximately 80.00% to approximately 125.00% of h ng / mL.
[0752] In some embodiments, the AUC0-8時間,定常状態 is the AUC 0-8時間,定常状態 7207 (CV 19%), within approximately 80.00% to approximately 125.00% of h ng / mL.
[0753] In some embodiments, the AUC of the unit dose after administration 0-8時間,定常状態 is the AUC 0-8時間,定常状態 7207 (CV 19%), within approximately 80.00% to approximately 125.00% of h ng / mL.
[0754] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is measured in plasma.
[0755] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the oral preparation to a human weighing about 8 kg to about 15 kg, max,定常状態 Within approximately 80.00% to approximately 125.00% of 533 ng / mL (5th and 95th percentiles of 368 to 770 ng / mL).
[0756] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the pharmaceutical composition to a human weighing about 8 kg to about 15 kg, max,定常状態 Within approximately 80.00% to approximately 125.00% of 533 ng / mL (5th and 95th percentiles of 368 to 770 ng / mL).
[0757] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose to a human weighing about 8 kg to about 15 kg, max,定常状態 Within approximately 80.00% to approximately 125.00% of 533 ng / mL (5th and 95th percentiles of 368 to 770 ng / mL).
[0758] In some embodiments, the AUC 0-8時間,定常状態After administration of the oral preparation to a human weighing about 8 kg to about 15 kg, the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2916 h·ng / mL (5th and 95th percentiles of 1924 to 4436 h·ng / mL).
[0759] In some embodiments, the AUC 0-8時間,定常状態 After administration of the pharmaceutical composition to a human weighing about 8 kg to about 15 kg, the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2916 h·ng / mL (5th and 95th percentiles of 1924 to 4436 h·ng / mL).
[0760] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 After administration of the unit dose to a human weighing about 8 kg to about 15 kg, the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2916 h·ng / mL (5th and 95th percentiles of 1924 to 4436 h·ng / mL).
[0761] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 15 kg to about 30 kg, after administration of the oral preparation, max,定常状態 Within approximately 80.00% to approximately 125.00% of 593 ng / mL (5th and 95th percentiles of 395 to 878 ng / mL).
[0762] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 15 kg to about 30 kg, after administration of the pharmaceutical composition, max,定常状態 Within approximately 80.00% to approximately 125.00% of 593 ng / mL (5th and 95th percentiles of 395 to 878 ng / mL).
[0763] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態Within approximately 80.00% to approximately 125.00% of 593 ng / mL (5th and 95th percentiles of 395 to 878 ng / mL).
[0764] In some embodiments, the AUC 0-8時間,定常状態 In humans weighing more than about 15 kg to about 30 kg, after administration of the oral formulation, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3043 h·ng / mL (5th and 95th percentiles of 1938 to 4763 h·ng / mL).
[0765] In some embodiments, the AUC 0-8時間,定常状態 In a human weighing more than about 15 kg to about 30 kg, after administration of the pharmaceutical composition, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3043 h·ng / mL (5th and 95th percentiles of 1938 to 4763 h·ng / mL).
[0766] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 In a human weighing more than about 15 kg to about 30 kg, after administration of the unit dose, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3043 h·ng / mL (5th and 95th percentiles of 1938 to 4763 h·ng / mL).
[0767] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 30 kg to about 55 kg, after administration of the oral preparation, max,定常状態 Within approximately 80.00% to approximately 125.00% of 679 ng / mL (5th and 95th percentiles of 450 to 1024 ng / mL).
[0768] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 30 kg to about 55 kg, after administration of the pharmaceutical composition, max,定常状態Within approximately 80.00% to approximately 125.00% of 679 ng / mL (5th and 95th percentiles of 450 to 1024 ng / mL).
[0769] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 679 ng / mL (5th and 95th percentiles of 450 to 1024 ng / mL).
[0770] In some embodiments, the AUC 0-8時間,定常状態 In humans weighing more than about 30 kg to about 55 kg, after administration of the oral formulation, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3149 h·ng / mL (5th and 95th percentiles of 2010 to 4855 h·ng / mL).
[0771] In some embodiments, the AUC 0-8時間,定常状態 In a human weighing more than about 30 kg to about 55 kg, after administration of the pharmaceutical composition, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3149 h·ng / mL (5th and 95th percentiles of 2010 to 4855 h·ng / mL).
[0772] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 In humans weighing more than about 30 kg to about 55 kg, after administration of the unit dose, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3149 h·ng / mL (5th and 95th percentiles of 2010 to 4855 h·ng / mL).
[0773] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the oral formulation, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 743 ng / mL (5th and 95th percentiles of 479 to 743 ng / mL).
[0774] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 55 kg, after administration of the pharmaceutical composition, max,定常状態 Within approximately 80.00% to approximately 125.00% of 743 ng / mL (5th and 95th percentiles of 479 to 743 ng / mL).
[0775] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 743 ng / mL (5th and 95th percentiles of 479 to 743 ng / mL).
[0776] In some embodiments, the AUC 0-8時間,定常状態 is the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3182 h·ng / mL (5th and 95th percentiles of 2057 to 4921 h·ng / mL).
[0777] In some embodiments, the AUC 0-8時間,定常状態 is the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3182 h·ng / mL (5th and 95th percentiles of 2057 to 4921 h·ng / mL).
[0778] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 is the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3182 h·ng / mL (5th and 95th percentiles of 2057 to 4921 h·ng / mL).
[0779] In some embodiments, the steady state geometric mean C max,定常状態After administration of the oral preparation to a human weighing about 8 kg to about 15 kg, max,定常状態 Within approximately 80.00% to approximately 125.00% of 352 ng / mL (5th and 95th percentiles of 240 to 514 ng / mL).
[0780] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the pharmaceutical composition to a human weighing about 8 kg to about 15 kg, max,定常状態 Within approximately 80.00% to approximately 125.00% of 352 ng / mL (5th and 95th percentiles of 240 to 514 ng / mL).
[0781] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose to a human weighing about 8 kg to about 15 kg, max,定常状態 Within approximately 80.00% to approximately 125.00% of 352 ng / mL (5th and 95th percentiles of 240 to 514 ng / mL).
[0782] In some embodiments, the AUC 0-8時間,定常状態 After administration of the oral preparation to a human weighing about 8 kg to about 15 kg, the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 1918 h·ng / mL (5th and 95th percentiles of 1255 to 2908 h·ng / mL).
[0783] In some embodiments, the AUC 0-8時間,定常状態 After administration of the pharmaceutical composition to a human weighing about 8 kg to about 15 kg, the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 1918 h·ng / mL (5th and 95th percentiles of 1255 to 2908 h·ng / mL).
[0784] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 After administration of the unit dose to a human weighing about 8 kg to about 15 kg, the AUC 0-8時間,定常状態Within approximately 80.00% to approximately 125.00% of 1918 h·ng / mL (5th and 95th percentiles of 1255 to 2908 h·ng / mL).
[0785] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 15 kg to about 22 kg, after administration of the oral preparation, max,定常状態 Within approximately 80.00% to approximately 125.00% of 473 ng / mL (5th and 95th percentiles of 323 to 688 ng / mL).
[0786] In some embodiments, the steady state geometric mean C max,定常状態 In a human weighing more than about 15 kg to about 22 kg, after administration of the pharmaceutical composition, max,定常状態 Within approximately 80.00% to approximately 125.00% of 473 ng / mL (5th and 95th percentiles of 323 to 688 ng / mL).
[0787] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 473 ng / mL (5th and 95th percentiles of 323 to 688 ng / mL).
[0788] In some embodiments, the AUC 0-8時間,定常状態 In humans weighing more than about 15 kg to about 22 kg, after administration of the oral formulation, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2479 h·ng / mL (5th and 95th percentiles of 1640 to 3771 h·ng / mL).
[0789] In some embodiments, the AUC 0-8時間,定常状態 In a human weighing more than about 15 kg to about 22 kg, after administration of the pharmaceutical composition, AUC 0-8時間,定常状態Within approximately 80.00% to approximately 125.00% of 2479 h·ng / mL (5th and 95th percentiles of 1640 to 3771 h·ng / mL).
[0790] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 In a human weighing more than about 15 kg to about 22 kg, after administration of the unit dose, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2479 h·ng / mL (5th and 95th percentiles of 1640 to 3771 h·ng / mL).
[0791] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 22 kg to about 38 kg, after administration of the oral preparation, max,定常状態 Within approximately 80.00% to approximately 125.00% of 522 ng / mL (5th and 95th percentiles of 349 to 770 ng / mL).
[0792] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 22 kg to about 38 kg, after administration of the pharmaceutical composition, max,定常状態 Within approximately 80.00% to approximately 125.00% of 522 ng / mL (5th and 95th percentiles of 349 to 770 ng / mL).
[0793] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 522 ng / mL (5th and 95th percentiles of 349 to 770 ng / mL).
[0794] In some embodiments, the AUC 0-8時間,定常状態 In humans weighing more than about 22 kg to about 38 kg, after administration of the oral formulation, AUC 0-8時間,定常状態Within approximately 80.00% to approximately 125.00% of 2557 h·ng / mL (5th and 95th percentiles of 1663 to 3942 h·ng / mL).
[0795] In some embodiments, the AUC 0-8時間,定常状態 In a human weighing more than about 22 kg to about 38 kg, after administration of the pharmaceutical composition, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2557 h·ng / mL (5th and 95th percentiles of 1663 to 3942 h·ng / mL).
[0796] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 In humans weighing more than about 22 kg to about 38 kg, after administration of the unit dose, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2557 h·ng / mL (5th and 95th percentiles of 1663 to 3942 h·ng / mL).
[0797] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 38 kg to about 55 kg, after administration of the oral preparation, max,定常状態 Within approximately 80.00% to approximately 125.00% of 651 ng / mL (5th and 95th percentiles of 435 to 974 ng / mL).
[0798] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 38 kg to about 55 kg, after administration of the pharmaceutical composition, max,定常状態 Within approximately 80.00% to approximately 125.00% of 651 ng / mL (5th and 95th percentiles of 435 to 974 ng / mL).
[0799] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態Within approximately 80.00% to approximately 125.00% of 651 ng / mL (5th and 95th percentiles of 435 to 974 ng / mL).
[0800] In some embodiments, the AUC 0-8時間,定常状態 In humans weighing more than about 38 kg to about 55 kg, after administration of the oral formulation, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2954 h·ng / mL (5th and 95th percentiles of 1958 to 4465 h·ng / mL).
[0801] In some embodiments, the AUC 0-8時間,定常状態 In a human weighing more than about 38 kg to about 55 kg, after administration of the pharmaceutical composition, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2954 h·ng / mL (5th and 95th percentiles of 1958 to 4465 h·ng / mL).
[0802] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 In humans weighing more than about 38 kg to about 55 kg, after administration of the unit dose, AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 2954 h·ng / mL (5th and 95th percentiles of 1958 to 4465 h·ng / mL).
[0803] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the oral formulation, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 739 ng / mL (5th and 95th percentiles of 483 to 1130 ng / mL).
[0804] In some embodiments, the steady state geometric mean C max,定常状態 In humans weighing more than about 55 kg, after administration of the pharmaceutical composition, max,定常状態 Within approximately 80.00% to approximately 125.00% of 739 ng / mL (5th and 95th percentiles of 483 to 1130 ng / mL).
[0805] In some embodiments, the steady state geometric mean C max,定常状態 After administration of the unit dose, C max,定常状態 Within approximately 80.00% to approximately 125.00% of 739 ng / mL (5th and 95th percentiles of 483 to 1130 ng / mL).
[0806] In some embodiments, the AUC 0-8時間,定常状態 is the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3191 h·ng / mL (5th and 95th percentiles of 2054 to 4948 h·ng / mL).
[0807] In some embodiments, the AUC 0-8時間,定常状態 is the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3191 h·ng / mL (5th and 95th percentiles of 2054 to 4948 h·ng / mL).
[0808] In some embodiments, the AUC of the unit dose 0-8時間,定常状態 is the AUC 0-8時間,定常状態 Within approximately 80.00% to approximately 125.00% of 3191 h·ng / mL (5th and 95th percentiles of 2054 to 4948 h·ng / mL).
[0809] In some embodiments, the exposure of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate increases dose-proportionally from about 31 mg to about 496 mg after a single oral dose, and max The estimated proportionality coefficient (90% CI) was 1,149 (1,07 to 1,20), and the AUC 0-inf In this case, the value is 1,027 (0.98 to 1.08).
[0810] In some embodiments, the overall t max The median range is 0.25 to 3.0 hours.
[0811] In some embodiments, the t max The median time is approximately 0.5 hours.
[0812] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is metabolized after ingestion.
[0813] In some embodiments, the metabolite of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is a cysteine conjugate.
[0814] In some embodiments, the metabolite of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is an O-glucuronide.
[0815] In some embodiments, the oral formulation has a shelf life of at least 24 months at about 20°C to about 25°C.
[0816] In some embodiments, the pharmaceutical composition has a shelf life of at least 24 months at about 20°C to about 25°C.
[0817] In some embodiments, the unit dose has a shelf life of at least 24 months at about 20°C to about 25°C.
[0818] In some embodiments, the oral formulation comprises ultra-pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0819] In some embodiments, the pharmaceutical composition comprises ultra-pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0820] In some embodiments, the unit dose comprises ultra-pure N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0821] Particle size distribution In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles with a preferred particle size distribution. In some embodiments, a pharmaceutical composition is provided that includes N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles with a preferred particle size distribution as described herein. Particle size distribution (PSD) can be measured using static automated imaging (Morphology4), as in Example 8 (Table 3A) shown herein. In some embodiments, PSD is measured using a Malvern Mastersizer, for example, a Malvern Mastersizer 3000. The method used in the present disclosure to measure PSD is described in detail in Example 11.
[0822] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 of about 0.5 μm to about 3.5 μm in a few CE size, for example, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D10 of about 0.5 μm to about 3.5 μm in a few CE size.
[0823] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D10 of about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1.0 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 2.1 μm, about 2.2 μm, about 2.3 μm, about 2.4 μm, about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, about 3.5 μm, about 3.6 μm, about 3.7 μm, about 3.8 μm, about 3.9 μm, about 4.0 μm, about 4.0 μm, about 4.1 μm, about 4.2 μm, about 4.3 μm, about 4.4 μm, about 4.5 μm, about 4.6 μm, about 4.7 μm, about 4.8 μm, about 4.9 μm, about 5.0 μm, about 5.1 μm, about 5.2 μm, about 5.3 μm, about 5.4 μm, about 5.5 μm, about 5.6 μm, about 5.7 μm, about 5.8 μm, about 5.9 μm, about 6.0 μm In one embodiment, particles are formed having a D10 particle size of about 0.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 2.1 μm, about 2.2 μm, about 2.3 μm, about 2.4 μm, about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, or about 3.5 μm.
[0824] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D10 of about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1.0 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 2.1 μm, about 2.2 μm, about 2.3 μm, about 2.4 μm, about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, about 3.5 μm, about 3.6 μm, about 3.7 μm, about 3.8 μm, about 3.9 μm, about 4.0 μm, about 4.0 μm, about 4.1 μm, about 4.2 μm, about 4.3 μm, about 4.4 μm, about 4.5 μm, about 4.6 μm, about 4.7 μm, about 4.8 μm, about 4.9 μm, about 5.0 μm, about 5.1 μm, about 5.2 μm, about 5.3 μm, about 5.4 μm, about 5.5 μm, about 5.6 μm, about 5.7 μm, about 5.8 μm, about 5.9 μm, about 6.0 μm In one embodiment, particles are formed having a D10 particle size of about 0.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 2.1 μm, about 2.2 μm, about 2.3 μm, about 2.4 μm, about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, or about 3.5 μm.
[0825] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 particle size of about 0.5 μm to about 3.5 μm, such as about 0.5 μm to about 1.0 μm, for example, about 1.0 μm to about 1.5 μm, for example, about 1.5 μm to about 2.0 μm, for example, about 2.0 μm to about 2.5 μm, for example, about 2.5 μm to about 3.0 μm, for example, about 3.0 μm to about 3.5 μm.
[0826] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 particle size of about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1.0 μm, about 1.1 μm, about 2.4 μm, or about 2.5 μm, a few CE diameters.
[0827] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D10 of about 2.0 μm to about 17.0 μm.
[0828] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D10 of about 2.0 μm, about 2.5 μm, about 3.0 μm, about 3.5 μm, about 4.0 μm, about 4.5 μm, about 5.0 μm, about 5.5 μm, about 6.0 μm, about 6.5 μm, about 7.0 μm, about 7.5 μm, about 8.0 μm, about 8.5 μm, about 9.0 μm, about 9.5 μm, about 10.0 μm, about 10.5 ... 0.5 μm, about 8.0 μm, about 8.5 μm, about 9.0 μm, about 9.5 μm, about 10.0 μm, about 10.5 μm, about 11.0 μm, about 11.5 μm, about 12.0 μm, about 12.5 μm, about 13.0 μm, about 13.5 μm, about 14.0 μm, about 14.5 μm, about 15.0 μm, about 15.5 μm, about 16.0 μm, about 16.5 μm, or about 17.0 μm.
[0829] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D10 of about 2.0 μm to about 17.0 μm, for example, about 2.0 μm to about 3.0 μm, for example, about 3.0 μm to about 4.0 μm, for example, about 4.0 μm to about 5.0 μm, for example, about 5.0 μm to about 6.0 μm, for example, about 6.0 μm to about 7.0 μm, for example, about 7. Particles having a D10 particle size of about 0.0 μm to about 8.0 μm, for example, about 8.0 μm to about 9.0 μm, for example, about 9.0 μm to about 10.0 μm, for example, about 10.0 μm to about 11.0 μm, for example, about 11.0 μm to about 12.0 μm, for example, about 12.0 μm to about 13.0 μm, for example, about 13.0 μm to about 14.0 μm, for example, about 14.0 μm to about 15.0 μm, for example, about 15.0 μm to about 16.0 μm, for example, about 16.0 μm to about 17.0 μm.
[0830] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 particle size by volume CE diameter of about 4.6 μm, about 6.2 μm, about 9.4 μm, about 10.7 μm, about 10.9 μm, about 11.2 μm, about 12.4 μm, about 12.6 μm, or about 13.1 μm.
[0831] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 of about 0.5 μm to about 5.0 μm in length.
[0832] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D length of about 0.5 μm, about 0.6 μm, about 0.7 μm, about 0.8 μm, about 0.9 μm, about 1.0 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 2.1 μm, about 2.2 μm, about 2.3 μm, about 2.4 μm, about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, about 3.5 μm, about 3.6 μm, about 3.7 μm, about 3.8 μm, about 3.9 μm, about 4.0 μm, about 4.1 μm, about 4.2 μm, about 4.3 μm, about 4.4 μm, about 4.5 μm, about 4.6 μm, about 4.7 μm, about 4.8 μm, about 4.9 μm, about 5.0 μm, about 5.1 μm, about 5.2 μm, about 5.3 μm, about 5.4 μm, about 5.5 μm, about 5.6 μm, about 5.7 μm, about 5.8 μm, about 5.9 μm, about 6.0 μm, about 6.1 μm, 0.3 μm, about 2.4 μm, or about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, about 3.5 μm, about 3.6 μm, about 3.7 μm, about 3.8 μm, about 3.9 μm, about 4.0 μm, about 4.1 μm, about 4.2 μm, about 4.3 μm, about 4.4 μm, or about 4.5 μm, about 4.6 μm, about 4.7 μm, about 4.8 μm, about 4.9 μm, or about 5.0 μm.
[0833] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 particle size of about 0.5 μm to about 5.0 μm, such as about 0.5 μm to about 1.0 μm, for example, about 1.0 μm to about 1.5 μm, for example, about 1.5 μm to about 2.0 μm, for example, about 2.0 μm to about 2.5 μm, for example, about 2.5 μm to about 3.0 μm, for example, about 3.0 μm to about 3.5 μm, for example, about 3.5 μm to about 4.0 μm, for example, about 4.0 μm to about 4.5 μm, for example, about 4.5 μm to about 5.0 μm.
[0834] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D10 particle size of about 1.1 μm, about 1.4 μm, about 1.5 μm, about 1.7 μm, about 1.8 μm, about 2.8 μm, about 2.9 μm, about 3.5 μm, or about 4.2 μm.
[0835] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D10 particle size measured using a Malvern Mastersizer 3000 of about 2.0 μm to about 20.0 μm.
[0836] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D10 particle size measured using a Malvern Mastersizer 3000 of about 2.0 μm, about 2.5 μm, about 3.0 μm, about 3.5 μm, about 4.0 μm, about 4.5 μm, about 5.0 μm, about 5.5 μm, about 6.0 μm, about 6.5 μm, about 7.0 μm, about 7.5 μm, about 8.0 μm, about 8.5 μm, about 9.0 μm, about 9.5 μm, about 10.0 μm, about 10.5 μm, about 11 μm, or about 12 μm. .0 μm, about 11.5 μm, about 12.0 μm, about 12.5 μm, about 13.0 μm, about 13.5 μm, about 14.0 μm, about 14.5 μm, about 15.0 μm, about 15.5 μm, about 16.0 μm, about 16.5 μm, about 17.0 μm, about 17.5 μm, about 18.0 μm, about 18.5 μm, about 19.0 μm, about 19.5 μm, and about 20.0 μm.
[0837] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D10 particle size measured using a Malvern Mastersizer 3000 of about 2.0 μm to about 20.0 μm, such as about 2.0 μm to about 2.5 μm, for example, about 2.5 μm to about 3.0 μm, for example, about 3.0 μm to about 3.5 μm, for example, about 3.5 μm to about 4.0 μm, for example, about 4.0 μm to about 4.5 μm, for example, about 4.5 μm to about 5.0 μm, for example, about 5.0 μm to about 5.5 μm, for example, about 5.5 μm to about 6.0 μm, for example, about 6.0 μm to about 7.0 μm, for example, about 7.0 μm to about 8.0 μm, for example, about 8.0 μm to about 9.0 μm, for example, about 9.0 μm to about 10 ... For example, about 6.0 μm to about 6.5 μm, for example, about 6.5 μm to about 7.0 μm, for example, about 7.0 μm to about 7.5 μm, for example, about 7.5 μm to about 8.0 μm, for example, about 8.0 μm to about 8.5 μm, for example, about 8.5 μm to about 9.0 μm, for example, about 9.0 μm to about 9.5 μm, for example, about 9.5 μm to about 10.0 μm, for example, about 10.0 μm to about 10.5 μm, for example, about 10.5 μm to about 11.0 μm , for example, about 11.0 μm to about 11.5 μm, for example, about 11.5 μm to about 12.0 μm, for example, about 12.0 μm to about 12.5 μm, for example, about 12.5 μm to about 13.0 μm, for example, about 13.0 μm to about 13.5 μm, for example, about 13.5 μm to about 14.0 μm, for example, about 14.0 μm to about 14.5 μm, for example, about 14.5 μm to about 15.0 μm, for example, about 15.0 μm to about 15.5 μm, e.g. For example, about 15.5 μm to about 16.0 μm, for example, about 16.0 μm to about 16.5 μm, for example, about 16.5 μm to about 17.0 μm, for example, about 17.0 μm to about 17.5 μm, for example, about 17.5 μm to about 18.0 μm, for example, about 18.0 μm to about 18.5 μm, for example, about 18.5 μm to about 19.0 μm, for example, about 19.0 μm to about 19.5 μm, for example, about 19.5 μm to about 20.0 μm.
[0838] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D50 of about 1.0 μm to about 10.0 μm in a few CE size, for example, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D50 of about 1.0 μm to about 10.0 μm in a few CE size.
[0839] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D50 of about 1.0 μm, about 1.1 μm, about 1.2 μm, about 1.3 μm, about 1.4 μm, about 1.5 μm, about 1.6 μm, about 1.7 μm, about 1.8 μm, about 1.9 μm, about 2.0 μm, about 2.1 μm, about 2.2 μm, about 2.3 μm, about 2.4 μm, about 2.5 μm, about 2.6 μm, about 2.7 μm, about 2.8 μm, about 2.9 μm, about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, about 3.5 μm, about 3.6 μm, about 3.7 μm, about 3.8 μm, about 3.9 μm, about 4.0 μm, about 4.1 μm, about 4.2 μm, about 4.3 μm, about 4.4 μm, about 4.5 μm, about 4.6 μm, about 4.7 μm, about 4.8 μm, about 4.9 μm, about 5.0 μm, about 5.1 μm, about 5.2 μm, about 5.3 μm, about 5.4 μm, about 5.5 μm, about 5.6 μm, about 5.7 μm, about 5.8 μm, about 5.9 μm, about 6.0 μm, about 6.1 μm, about 6.2 μm, about 6.3 μm, about 6.4 μm, about 6.5 μm, about 6.6 μm 3μm, about 2.4μm, about 2.5μm, about 2.6μm, about 2.7μm, about 2.8μm, about 2.9μm, about 3.0μm, about 3.1μm, about 3.2μm, about 3.3μm, about 3.4μm, about 3.5μm, about 3.6μm , about 3.7μm, about 3.8μm, about 3.9μm, about 4.0μm, about 4.1μm, about 4.2μm, about 4.3μm, about 4.4μm, about 4.5μm, about 4.6μm, about 4.7μm, about 4.8μm, about 4.9μm, about 5 .0μm, about 5.1μm, about 5.2μm, about 5.3μm, about 5.4μm, about 5.5μm, about 5.6μm, about 5.7μm, about 5.8μm, about 5.9μm, about 6.0μm, about 6.1μm, about 6.2μm, about 6.3μm m, approximately 6.4μm, approximately 6.5μm, approximately 6.6μm, approximately 6.7μm, approximately 6.8μm, approximately 6.9μm, approximately 7.0μm, approximately 7.1μm, approximately 7.2μm, approximately 7.3μm, approximately 7.4μm, approximately 7.5μm, approximately 7.6μm, approximately Particles are formed having a D50 particle size of 7.7 μm, about 7.8 μm, about 7.9 μm, about 8.0 μm, about 8.1 μm, about 8.2 μm, about 8.3 μm, about 8.4 μm, about 8.5 μm, about 8.6 μm, about 8.7 μm, about 8.8 μm, about 8.9 μm, about 9.0 μm, about 9.1 μm, about 9.2 μm, about 9.3 μm, about 9.4 μm, about 9.5 μm, about 9.6 μm, about 9.7 μm, about 9.8 μm, about 9.9 μm, or about 10.0 μm.
[0840] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D50 particle size of about 1.0 μm to about 10.0 μm, for example, about 1.0 μm to about 2.0 μm, for example, about 2.0 μm to about 3.0 μm, for example, about 3.0 μm to about 4.0 μm, for example, about 4.0 μm to about 5.0 μm, for example, about 5.0 μm to about 6.0 μm, for example, about 6.0 μm to about 7.0 μm, for example, about 7.0 μm to about 8.0 μm, for example, about 8.0 μm to about 9.0 μm, for example, about 9.0 μm to about 10.0 μm.
[0841] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D50 particle size of about 1.6 μm, about 2.0 μm, about 2.2 μm, about 2.5 μm, about 2.9 μm, about 3.3 μm, about 5.6 μm, or about 5.3 μm in a few CE diameters.
[0842] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D50 of about 10.0 μm to about 39.0 μm.
[0843] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D50 of about 10.0 μm, about 11.0 μm, about 12.0 μm, about 13.0 μm, about 14.0 μm, about 15.0 μm, about 16.0 μm, about 17.0 μm, about 18.0 μm, about 19.0 μm, about Particles are formed having a D50 particle size of 20 μm, about 21.0 μm, about 22.0 μm, about 23.0 μm, about 24.0 μm, about 25.0 μm, about 26.0 μm, about 27.0 μm, about 28.0 μm, about 29.0 μm, about 30.0 μm, about 31.0, about 32.0 μm, about 33.0 μm, about 34.0 μm, about 35.0 μm, about 36.0 μm, about 37.0 μm, about 38.0 μm, or about 39.0 μm.
[0844] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D50 of about 10.0 μm to about 39.0 μm, for example, about 10.0 μm to about 12.0 μm, for example, about 12.0 μm to about 14.0 μm, for example, about 14.0 μm to about 16.0 μm, for example, about 16.0 μm to about 18.0 μm, for example, about 18.0 μm to about 20.0 μm, e.g. For example, particles having a D50 particle size of about 20.0 μm to about 22.0 μm, for example, about 22.0 μm to about 24.0 μm, for example, about 24.0 μm to about 26.0 μm, for example, about 26.0 μm to about 28.0 μm, for example, about 28.0 μm to about 30.0 μm, for example, about 30.0 to about 32.0 μm, for example, about 32.0 μm to about 34.0 μm, for example, about 34.0 μm to about 36.0 μm, for example, about 36.0 μm to about 38.0 μm, for example, about 38.0 μm to about 39.0 are formed.
[0845] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D50 particle size by volume CE diameter of about 11.1 μm, about 14.0 μm, about 20.6 μm, about 22.7 μm, about 24.7 μm, about 25.0 μm, about 26.0 μm, about 26.4 μm, about 32.1 μm, or about 38.9 μm.
[0846] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D50 in the range of about 3.0 μm to about 12.0 μm.
[0847] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D50 of about 3.0 μm, about 3.1 μm, about 3.2 μm, about 3.3 μm, about 3.4 μm, about 3.5 μm, about 3.6 μm, about 3.7 μm, about 3.8 μm, about 3.9 μm, about 4.0 μm, about 4.1 μm, about 4.2 μm, about 4.3 μm, about 4.4 μm, about 4.5 μm, about 4.6 μm, about 4.7 μm, about 4.8 μm, about 4.9 μm, about 5.0 μm, about 5.1 μm, about 5.2 μm, about 5.3 μm, about 5.4 μm, about 5.5 μm, about 5.6 μm, about 5.7 μm, about 5.8 μm, about 5.9 μm, about 6.0 μm, about 6.1 μm, about 6.2 μm, about 6.3 μm, about 6.4 μm, about 6.5 μm, about 6.6 μm, about 6.7 μm, about 6.8 μm, about 6.9 μm, about 7.0 μm, about 7.1 μm, about 7.2 μm, about 7.3 μm, about 7.4 μm, about 7.5 μm, about 7.6 μm, about 7.7 μm, about 7.8 μm, about 7.9 μm, about 8.0 μm, about 8.1 μm, about 8.2 μm, about 8.3 μm, about 8.4 μm, about 8.5 μm, about 8.6 μm .4μm, about 4.5μm, about 4.6μm, about 4.7μm, about 4.8μm, about 4.9μm, about 5.0μm, about 5.1μm, about 5.2μm, about 5.3μm, about 5.4μm, about 5.5μm, about 5.6μm, about 5.7μm, Approximately 5.8μm, approximately 5.9μm, approximately 6.0μm, approximately 6.1μm, approximately 6.2μm, approximately 6.3μm, approximately 6.4μm, approximately 6.5μm, approximately 6.6μm, approximately 6.7μm, approximately 6.8μm, approximately 6.9μm, approximately 7.0μm, approximately 7.1μm , about 7.2μm, about 7.3μm, about 7.4μm, about 7.5μm, about 7.6μm, about 7.7μm, about 7.8μm, about 7.9μm, about 8.0μm, about 8.1μm, about 8.2μm, about 8.3μm, about 8.4μm, about 8.5 μm, approximately 8.6 μm, approximately 8.7 μm, approximately 8.8 μm, approximately 8.9 μm, approximately 9.0 μm, approximately 9.1 μm, approximately 9.2 μm, approximately 9.3 μm, approximately 9.4 μm, approximately 9.5 μm, approximately 9.6 μm, approximately 9.7 μm, approximately 9.8 μm, approximately 9 0.9 μm, about 10.0 μm, about 10.1 μm, about 10.2 μm, about 10.3 μm, about 10.4 μm, about 10.5 μm, about 10.6 μm, about 10.7 μm, about 10.8 μm, about 10.9 μm, about 11.0 μm, about 11.1 μm, about 11.2 μm, about 11.3 μm, about 11.4 μm, about 11.5 μm, about 11.6 μm, about 11.7 μm, about 11.8 μm, about 11.9 μm, or about 12.0 μm.
[0848] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D50 of about 3.0 μm to about 12.0 μm, for example, about 3.0 μm to about 3.5 μm, for example, about 3.5 μm to about 4.0 μm, for example, about 4.0 μm to about 4.5 μm, for example, about 4.5 μm to about 5.0 μm, for example, about 5.0 μm to about 5.5 μm, for example, about 5.5 μm to about 6.0 μm, for example, about 6.0 μm to about 6. 0.5 μm, for example, about 6.5 μm to about 7.0 μm, for example, about 7.0 μm to about 7.5 μm, for example, about 7.5 μm to about 8.0 μm, for example, about 8.0 μm to about 8.5 μm, for example, about 8.5 μm to about 9.0 μm, for example, about 9.0 μm to about 9.5 μm, for example, about 9.5 μm to about 10.0 μm, for example, about 10.0 μm to about 10.5 μm, for example, about 10.5 μm to about 11.0 μm, for example, about 11.0 μm to about 11.5 μm, for example, about 11.5 μm to about 12.0 μm.
[0849] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D50 particle size of about 3.2 μm, about 3.6 μm, about 4.0 μm, about 4.1 μm, about 4.7 μm, about 6.2 μm, about 7.0 μm, about 7.4 μm, or about 9.5 μm in length.
[0850] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a few CE size D90 of about 5.0 μm to about 22.0 μm.
[0851] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D50 particle size measured using a Malvern Mastersizer 3000 of about 5.0 μm to about 60.0 μm.
[0852] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D50 particle size of about 5 μm, about 6 μm, about 7 μm, about 8 μm, about 9 μm, about 10 μm, about 11 μm, about 12 μm, about 13 μm, about 14 μm, about 15 μm, about 16 μm, about 17 μm, about 18 μm, about 19 μm, about 20 μm, about 21 μm, about 22 μm, about 23 μm, about 24 μm, about 25 μm, about 26 μm, about 27 μm, about 28 μm, about 29 μm, about 30 μm, about 31 μm, about 32 μm, about 33 μm, about 34 μm, about 35 μm, about 36 μm, about 37 μm, about 38 μm, about 39 μm, about 40 μm, about 41 μm, about 42 μm, about 43 μm, about 44 μm, about 45 μm, about 46 μm, about 47 μm, about 48 μm, about 49 μm, about 50 μm, about 51 μm, about 52 μm, about 53 μm, about 54 μm, about 55 μm, about 56 μm, about 57 μm, about 58 μm, about 59 μm, or about 60 μm.
[0853] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles are prepared by a Malvern Mastersizer. 3000, the D50 particle size is about 5.0 μm to about 60.0 μm, for example, about 5.0 μm to about 6.0 μm, for example, about 6.0 μm to about 7.0 μm, for example, about 7.0 μm to about 8.0 μm, for example, about 8.0 μm to about 9.0 μm, for example, about 9.0 μm to about 10.0 μm, for example, about 10.0 μm to about 11.0 μm, for example, about 11.0 μm to about 12.0 μm, for example, about 12.0 μm to about 13.0 μm, for example, about 13.0 μm to about 14.0 μm, for example, about 14.0 μm to about 15.0 μm, for example, about 15.0 μm to about 16.0 μm, for example, about 16.0 μm to about 17.0 μm, for example, about 17.0 μm to about 18.0 μm, for example, about 19.0 μm to about 20.0 μm, for example, about 20.0 μm to about 21.0 μm, for example, about 21.0 μm to about 22.0 μm, for example, about 22.0 μm to about 23.0 μm, for example, about 23.0 μm to about 24.0 μm, for example, about 24.0 μm to about 25.0 μm, for example, about 25.0 μm to about 26.0 μm, for example, about 26.0 μm to about 2 7.0 μm, for example, about 27.0 μm to about 28.0 μm, for example, about 28.0 μm to about 29.0 μm, for example, about 29.0 μm to about 30.0 μm, for example, about 30.0 μm to about 31.0 μm, for example, about 31.0 μm to about 32.0 μm, for example, about 32.0 μm to about 33.0 μm, for example, about 33.0 μm to about 34.0 μm, for example, about 34.0 μm to about 35.0 μm, for example, about 35.0 μm to about 36.0 μm, for example, about 36.0 μm to about 37.0 μm, for example, about 37.0 μm to about 38 .0 μm, for example, about 38.0 μm to about 39.0 μm, for example, about 39.0 μm to about 40.0 μm, for example, about 40.0 μm to about 41.0 μm, for example, about 41.0 μm to about 42.0 μm, for example, about 42.0 μm to about 43.0 μm, for example, about 43.0 μm to about 44.0 μm, for example, about 44.0 μm to about 45.0 μm, for example, about 45.0 μm to about 46.0 μm, for example, about 46.0 μm to about 47.0 μm, for example, about 47.0 μm to about 48.0 μm, for example, about 48.0 μm to about 49.0 μm, for example, about 49.0 μm to about 50.0 μm, for example, about 50.0 μm to about 51.0 μm, for example, about 51.0 μm to about 52.0 μm, for example, about 52.0 μm to about 53.0 μm, for example, about 53.0 μm to about 54.0 μm, for example, about 54.0 μm to about 55.0 μm, for example, about 55.0 μm to about 56.0 μm, for example, about 56.0 μm to about 57.0 μm, for example, about 57.0 μm to about 58.0 μm, for example, about 58.0 μm to about 59.0 μm, or for example, about 59.0 μm to about 60.0 μm.
[0854] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D90 of about 5.0 μm, about 5.5 μm, about 6.0 μm, about 6.5 μm, about 7.0 μm, about 7.5 μm, about 8.0 μm, about 8.5 μm, about 9.0 μm, about 9.5 μm, about 10.0 μm, about 10.5 μm, about 11.0 μm, about 11.5 μm, about 12.0 μm, about 12.5 μm, about 13.0 μm, about 14.0 μm, about 14.5 μm, about 15.0 μm, about 15.5 μm, about 16.0 μm, about 16.5 μm, about 17.0 μm, about 17.5 μm, about 18.0 μm, about 18.5 μm, about 19.0 μm, about 19.5 μm, about 20.0 μm, about 20.5 μm, about 21.0 μm, about 22.0 μm, about 23.0 μm, about 24.0 μm, about 25.0 μm, about 26.0 μm, about 27.0 μm, about 28.0 μm, about 29.0 μm, about 30.0 μm, about 31.0 μm, about 32.0 μm, about 33.0 μm, about 34.0 μm, about 35.0 μm, about 36.0 μm, about 37.0 μm, about 38.0 μm, about 39.0 μm, about 40.0 μm, about 40.0 5 μm, about 12.0 μm, about 12.5 μm, about 13.0 μm, about 13.5 μm, about 14.0 μm, about 14.5 μm, about 15.0 μm, about 15.5 μm, about 16.0 μm, about 16.5 μm, about 17.0 μm, about 17.5 μm, about 18.0 μm, about 18.5 μm, about 19.0 μm, about 19.5 μm, about 20.0 μm, about 20.5 μm, about 21.0 μm, about 21.5 μm, or about 22.0 μm.
[0855] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D90 of several CE diameters of about 5.0 μm to about 22.0 μm, for example, about 5.0 μm to about 6.0 μm, for example, about 6.0 μm to about 7.0 μm, for example, about 7.0 μm to about 8.0 μm, for example, about 8.0 μm to about 9.0 μm, for example, about 9.0 μm to about 10.0 μm, for example, about 10.0 μm to about 11.0 μm, for example, about 11.0 μm. The resulting particles have a D90 particle size of about 1.5 μm to about 12.0 μm, for example, about 12.0 μm to about 13.0 μm, for example, about 13.0 μm to about 14.0 μm, for example, about 14.0 μm to about 15.0 μm, for example, about 15.0 μm to about 16.0 μm, for example, about 16.0 μm to about 17.0 μm, for example, about 17.0 μm to about 18.0 μm, for example, about 18.0 μm to about 19.0 μm, for example, about 19.0 μm to about 20.0 μm, for example, about 20.0 μm to about 21.0 μm, for example, about 21.0 μm to about 22.0 μm.
[0856] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D90 particle size of about 5.8 μm, about 7.4 μm, about 9.4 μm, about 10.1 μm, about 10.7 μm, about 13.3 μm, about 14.1 μm, about 15.0 μm, or about 17.8 μm in several CE diameters.
[0857] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D90 of about 10.0 μm to about 55.0 μm, for example, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a volume CE diameter D90 of about 10.0 μm to about 55.0 μm.
[0858] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D90 of about 25.0 μm to about 55.0 μm.
[0859] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D90 of about 25.0 μm, about 26.0 μm, about 27.0 μm, about 28.0 μm, about 29.0 μm, about 30.0 μm, about 31.0 μm, about 32.0 μm, about 33.0 μm, about 34.0 μm, about 35.0 μm , to form particles having a D90 particle size of about 36.0 μm, about 37.0 μm, about 38.0 μm, about 39.0 μm, about 40.0 μm, about 41.0 μm, about 42.0 μm, about 43.0 μm, about 44.0 μm, about 45.0 μm, about 46.0 μm, about 47.0 μm, about 48.0 μm, about 49.0 μm, about 50.0 μm, about 51.0 μm, about 52.0 μm, about 53.0 μm, about 54.0 μm, or about 55.0 μm.
[0860] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D90 of about 25.0 μm to about 55.0 μm, for example, about 25.0 μm to about 30.0 μm, for example, about 30.0 μm to about 35.0 μm, for example, about 35.0 μm to about 40.0 μm, for example, about 40.0 μm to about 45.0 μm, for example, about 45.0 μm to about 50.0 μm, for example, about 50.0 μm to about 55.0 μm.
[0861] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D90 particle size of about 26.7 μm, about 34.5 μm, about 35.0 μm, about 36.0 μm, about 37.6 μm, about 43.5 μm, about 44.4 μm, about 47.1 μm, or about 52.2 μm.
[0862] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter, D[4,3], of about 8.0 μm to about 40.0 μm.
[0863] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D[4,3] of about 8.0 μm, about 9.0 μm, about 10.0 μm, about 11.0 μm, about 12.0 μm, about 13.0 μm, about 14.0 μm, about 15.0 μm, about 16.0 μm, about 17.0 μm, about 18.0 μm, about 19.0 μm, about 20.0 μm, about 21.0 μm, about 22.0 μm, about 23.0 μm, about 24.0 μm, about 25.0 μm, about 26.0 μm, about 27.0 μm, about 28.0 μm, about 29.0 μm, about 30.0 μm, about 31.0 μm, about 32.0 μm, about 33.0 μm, about 34.0 μm, about 35.0 μm, about 36.0 μm, about 37.0 μm, about 38.0 μm, about 39.0 μm, about 40.0 μm, about 41.0 μm, about 42.0 μm, about 43.0 μm, about 44.0 μm, about 45.0 μm, about 46.0 μm, about 47.0 μm, about 48.0 μm, about 49.0 μm, about 50.0 μm, about 51.0 μm, about 52.0 μm, about 53.0 μm, about 54.0 μm, about 55.0 μm, about 56.0 μm, about 57.0 μm, In one embodiment, the method comprises the steps of: forming particles having a D90 particle size of about 20.0 μm, about 21.0 μm, about 22.0 μm, about 23.0 μm, about 24.0 μm, about 25.0 μm, about 26.0 μm, about 27.0 μm, about 28.0 μm, about 29.0 μm, about 30.0 μm, about 31.0 μm, about 32.0 μm, about 33.0 μm, about 34.0 μm, about 35.0 μm, about 36.0 μm, about 37.0 μm, about 38.0 μm, about 39.0 μm, or about 40.0 μm.
[0864] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D[4,3] of about 8.0 μm to about 40.0 μm, such as about 8.0 μm to about 12.0 μm, for example, about 12.0 μm to about 16.0 μm, for example, about 16.0 μm to about 20.0 μm, for example, about 20.0 μm to about 24.0 μm, for example, about 24.0 μm to about 28.0 μm, for example, about 28.0 μm to about 32.0 μm, for example, about 32.0 μm to about 36.0 μm, for example, about 36.0 μm to about 40.0 μm.
[0865] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D[4,3] of about 13.7 μm, about 17.1 μm, about 22.1 μm, about 23.3 μm, about 25.4 μm, about 25.7 μm, about 27.1 μm, about 29.5 μm, about 38.8 μm, or about 39.4 μm, D90 particle size.
[0866] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter, D[3,2], of about 5.0 μm to about 30.0 μm.
[0867] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a volume CE diameter D[3,2] of about 5.0 μm, about 6.0 μm, about 7.0 μm, about 8.0 μm, about 9.0 μm, about 10.0 μm, about 11.0 μm, about 12.0 μm, about 13. In one embodiment, particles are formed having a D90 particle size of about 10.0 μm, about 14.0 μm, about 15.0 μm, about 16.0 μm, about 17.0 μm, about 18.0 μm, about 19.0 μm, about 20.0 μm, about 21.0 μm, about 22.0 μm, about 23.0 μm, about 24.0 μm, about 25.0 μm, about 26.0 μm, about 27.0 μm, about 28.0 μm, about 29.0 μm, or about 30.0 μm.
[0868] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D[3,2] of about 5.0 μm to about 30.0 μm, such as about 5.0 μm to about 10.0 μm, for example, about 10.0 μm to about 15.0 μm, for example, about 15.0 μm to about 20.0 μm, for example, about 20.0 μm to about 25.0 μm, for example, about 25.0 μm to about 30.0 μm.
[0869] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a volume CE diameter D[3,2] D90 particle size of about 8.8 μm, about 11.4 μm, about 17.7 μm, about 17.5 μm, about 17.9 μm, about 19.5 μm, about 20.5 μm, about 21.8 μm, about 24.2 μm, or about 34.2 μm.
[0870] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D90 length of about 10.0 μm to about 20.0 μm.
[0871] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having an average number CE diameter of about 1.0 μm to about 12.0 μm.
[0872] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having an average number CE diameter of about 1.0 μm, about 1.5 μm, about 2.0 μm, about 2.5 μm, about 3.0 μm, about 3.5 μm, about 4.0 μm, about 4.5 μm, about 5.0 μm, about 5.5 μm, about 6.0 μm, about 6.5 μm, about 7.0 μm, about 7.5 μm, about 8.0 μm, about 8.5 μm, about 9.0 μm, about 9.5 μm, about 10.0 μm, about 10.5 μm, about 11.0 μm, about 11.5 μm, or about 12.0 μm.
[0873] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has an average number C E diameter of about 1.0 μm to about 12.0 μm, for example, about 1.0 μm to about 2.0 μm, for example, about 2.0 μm to about 3.0 μm, for example, about 3.0 μm to about 4.0 μm. , for example, about 4.0 μm to about 5.0 μm, for example, about 5.0 μm to about 6.0 μm, for example, about 6.0 μm to about 7.0 μm, for example, about 7.0 μm to about 8.0 μm, for example, about 8.0 μm to about 9.0 μm, for example, about 9.0 μm to about 10.0 μm, for example, about 10.0 μm to about 11.0 μm, for example, about 11.0 μm to about 12.0 μm.
[0874] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having an average number CE diameter of about 2.9 μm, about 3.4 μm, about 3.7 μm, about 4.2 μm, about 4.6 μm, about 5.3 μm, about 5.8 μm, about 6.7 μm, about 7.7 μm, or about 8.2 μm.
[0875] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D90 particle size of about 10.0 μm, about 10.5 μm, about 11.0 μm, about 11.5 μm, about 12.0 μm, about 12.5 μm, about 13.0 μm, about 13.5 μm, about 14.0 μm, about 14.5 μm, about 15.0 μm, about 15.5 μm, about 16.0 μm, about 16.5 μm, about 17.0 μm, about 17.5 μm, about 18.0 μm, about 18.5 μm, about 19.0 μm, about 19.5 μm, or about 20.0 μm.
[0876] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate has a D90 of about 10.0 μm to about 20.0 μm, for example, about 10.0 μm to about 11.0 μm, for example, about 11.0 μm to about 12.0 μm, for example, about 12.0 μm to about 1 Particles having a D90 particle size of 3.0 μm, for example, about 13.0 μm to about 14.0 μm, for example, about 14.0 μm to about 15.0 μm, for example, about 15.0 μm to about 16.0 μm, for example, about 16.0 μm to about 17.0 μm, for example, about 17.0 μm to about 18.0 μm, for example, about 18.0 μm to about 19.0 μm, for example, about 19.0 μm to about 20.0 μm are formed.
[0877] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D90 particle size of about 10.5 μm, about 13.9 μm, about 16.6 μm, about 16.8 μm, about 22.2 μm, about 24.8 μm, about 25.5 μm, or about 26.7 μm.
[0878] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate forms particles having a D90 particle size having a D90 of about 7.0 μm to about 35.0 μm in several lengths.
[0879] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D90 particle size of about 30.0 μm to about 130.0 μm as measured using a Malvern Mastersizer 3000.
[0880] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles have a D90 particle size of about 30 μm, about 35 μm, about 40 μm, about 45 μm, about 50 μm, about 55 μm, about 60 μm, about 65 μm, about 70 μm, about 75 μm, about 80 μm, about 85 μm, about 90 μm, about 95 μm, about 100 μm, about 105 μm, about 110 μm, about 115 μm, about 120 μm, about 125 μm, or about 130 μm as measured using a Malvern Mastersizer 3000.
[0881] In some embodiments, the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate particles are prepared by a Malvern Mastersizer. The D90 particle size measured using a 3000 is about 30.0 μm to about 130.0 μm, for example, about 30.0 μm to about 35.0 μm, for example, about 35.0 μm to about 40.0 μm, for example, about 40.0 μm to about 45.0 μm, for example, about 45.0 μm to about 50.0 μm, for example, about 50.0 μm to about 55.0 μm, for example, about 55.0 μm to about 60.0 μm, for example, about 60.0 μm to about 65.0 μm, for example, about 65.0 μm to about 70.0 μm, for example, about 70.0 μm to about 75.0 μm, for example, about 75.0 μm m to about 80.0 μm, for example, about 80.0 μm to about 85.0 μm, for example, about 85.0 μm to about 90.0 μm, for example, about 90.0 μm to about 95.0 μm, for example, about 95.0 μm to about 100.0 μm, for example, about 100.0 μm to about 105.0 μm, for example, about 105.0 μm to about 110.0 μm, for example, about 110.0 μm to about 115.0 μm, for example, about 115.0 μm to about 120.0 μm, for example, about 120.0 μm to about 125.0 μm, or for example, about 125.0 μm to about 130.0 μm.
[0882] Terms 1. ORZY-01, [ka] A process for preparing Step 1A) Reacting a compound of formula (I), [ka] in a vessel, a compound of formula (II), [ka] in a first solvent at a first temperature for more than two hours to obtain an intermediate; and Step 1B) reacting the intermediate with NaNO2 in a second solvent at a second temperature to obtain ORZY-01, thereby obtaining ORZY-01.
[0883] 2. ORZY-01, [ka] A process for preparing Step 1A) Reacting a compound of formula (I), [ka] in a vessel, a compound of formula (II), [ka] in a first solvent at a first temperature to obtain an intermediate; and then Step 1B) reacting the intermediate with NaNO2 in a second solvent at a second temperature to obtain ORZY-01, thereby obtaining ORZY-01.
[0884] 3. The process according to any one of the preceding clauses, wherein prior to step 1B), the intermediate is isolated and optionally purified.
[0885] 4. The process of any one of the preceding clauses, wherein the first solvent is a polar protic solvent or a mixture of polar protic solvents.
[0886] 5. The process of any one of the preceding clauses, wherein the first solvent is selected from the group consisting of ethanol, water, methanol, 2-propanol, and any mixture thereof.
[0887] 6. The process of any one of the preceding clauses, wherein the first solvent is a mixture of ethanol and water.
[0888] 7. The process of any one of the preceding clauses, wherein step 1A is carried out under basic conditions, e.g., by addition of a hydroxide, e.g., NaOH or KOH.
[0889] 8. The process of any one of the preceding clauses, wherein the second solvent is a chlorinated hydrocarbon or a mixture containing a chlorinated hydrocarbon.
[0890] 9. The process of any one of the preceding clauses, wherein the second solvent is a mixture of dichloromethane and water.
[0891] 10. The process of any one of the preceding clauses, wherein the first solvent is different from the second solvent.
[0892] 11. The process of any one of the preceding clauses, wherein the first temperature is the boiling point of the solvent.
[0893] 12. The process of any one of the preceding clauses, wherein the first temperature is higher than the second temperature.
[0894] 13. The process of any one of the preceding clauses, wherein the first temperature is from 70°C to 90°C, such as from 72°C to 88°C, such as from 74°C to 86°C, such as from 76°C to 84°C, such as from 78°C to 82°C, such as 80°C.
[0895] 14. The process according to any one of the preceding clauses, wherein the second temperature is 0°C to 15°C, such as 0°C to 1°C, for example, 1°C to 2°C, for example, 2°C to 3°C, for example, 3°C to 4°C, for example, 5°C to 6°C, for example, 6°C to 7°C, for example, 7°C to 8°C, for example, 8°C to 9°C, for example, 9°C to 10°C, for example, 10°C to 11°C, for example, 11°C to 12°C, for example, 12°C to 13°C, for example, 13°C to 14°C, for example, 14°C to 15°C.
[0896] 15. The process of any one of the preceding clauses, wherein the second temperature is maintained for 1 hour.
[0897] 16. The process according to any one of the preceding clauses, wherein the compound of formula (II) is mixed with the compound of formula (I) in a molar ratio of 1.3:1.0.
[0898] 17. The process of any one of the preceding clauses, wherein the intermediate is not isolated prior to reaction with NaNO2.
[0899] 18. The process of any one of the preceding clauses, wherein the intermediate is reacted with at least 1.2 equivalents of NaNO2.
[0900] 19. The process according to any one of the preceding clauses, wherein the intermediate is reacted with 1.2 to 1.6 equivalents of NaNO2.
[0901] 20. The process of any one of the preceding clauses, wherein the first solvent is heated to reflux for at least 2.5 hours, such as 3 hours or more, such as 4 hours or more, such as 5 hours or more, for example, 6 hours or more.
[0902] 21. The process of any one of the preceding clauses, wherein the first solvent is heated to 75°C to 85°C, e.g., 80°C, for at least 3.5 hours.
[0903] 22. The process of any one of the preceding clauses, wherein the first solvent is a mixture of ethanol and water, optionally denatured, and the first solvent is maintained at 80°C for at least 3 hours.
[0904] 23. The process of any one of the preceding clauses, wherein the first solvent is a mixture of ethanol and water, optionally denatured, and the first solvent is maintained at 80°C for at least 3 hours, and the second solvent is a mixture of dichloromethane and water.
[0905] 24.ORZY-03, [ka] A process for the preparation of a compound comprising the following successive steps: a) ORZY-01, [ka] with dibenzoyl L-tartaric acid (L-DBTA) in a first step 2 solvent in a vessel, heating said first step 2 solvent to a first step 2 temperature, and optionally stirring said first step 2 solvent; b) cooling the solvent of the first step 2 to a temperature of a second step 2 at a cooling rate of at least 15 K / h to obtain a solid composition comprising ORZY-03, wherein the temperature of the first step 2 is higher than the temperature of the second step 2; and c) separating the solvent of the first step 2 from the solid composition comprising ORZY-03, optionally wherein said separating is by filtration; thereby obtaining ORZY-03.
[0906] 25.Furthermore, d) washing said solid composition comprising ORZY-03 one or more times with a first predetermined volume of said first step 2 solvent.
[0907] 26.Furthermore, 26. The process according to any one of clauses 24 to 25, comprising the step of: e) drying the solid composition comprising ORZY-03 under reduced pressure.
[0908] 27. The process according to any one of clauses 24 to 26, further comprising a step a1) prior to step b), wherein the solvent of the first step 2 is cooled to a temperature of a third step 2, the temperature of the third step 2 being higher than the temperature of the second step 2.
[0909] 28. The process of any one of clauses 24-27, wherein the cooling rate is selected from the group consisting of 15K / h, 16K / h, 17K / h, 18K / h, 19K / h, 20K / h, 21K / h, 22K / h, 23K / h, 24K / h, 25K / h, 26K / h, 27K / h, 28K / h, 29K / h, 30K / h, 31K / h, 32K / h, 33K / h, 34K / h, 35K / h, 36K / h, 37K / h, 38K / h, 39K / h, 40K / h, 41K / h, 42K / h, 43K / h, 44K / h, 45K / h, 46K / h, 47K / h, 48K / h, 49K / h, and 50K / h.
[0910] 29. The cooling rate is 15K / h to 50K / h, for example, 15K / h to 16K / h, for example, 16K / h to 17K / h, for example, 17K / h to 18K / h, for example, 18K / h to 19K / h, for example, 19K / h to 20K / h, for example, 20K / h to 21K / h, for example, 21K / h to 22K / h, for example, 22K / h to 23K / h, for example For example, 23K / h to 24K / h, for example, 24K / h to 25K / h, for example, 25K / h to 26K / h, for example, 26K / h to 27K / h, for example, 27K / h to 28K / h, for example, 28K / h to 29K / h, for example, 29K / h to 30K / h, for example, 30K / h to 31K / h, for example, 31K / h to 32K / h, for example, 32K / h ~33K / h, for example, 33K / h~34K / h, for example, 34K / h~35K / h, for example, 35K / h~36K / h, for example, 36K / h~37K / h, for example, 37K / h~38K / h, for example, 38K / h~39K / h, for example, 39K / h~40K / h, for example, 40K / h~41K / h, for example, 41K / h~42K / h, for example 29. The process according to any one of clauses 24 to 28, wherein the reaction volume is, for example, 42K / h to 43K / h, for example, 43K / h to 44K / h, for example, 44K / h to 45K / h, for example, 45K / h to 46K / h, for example, 46K / h to 47K / h, for example, 47K / h to 48K / h, for example, 48K / h to 49K / h, for example, 49K / h to 50K / h.
[0911] 30. The process of any one of clauses 24 to 29, wherein the cooling rate is from 15K / h to 50K / h.
[0912] 31. The process of any one of clauses 24 to 30, wherein the cooling rate is between 15K / h and 40K / h.
[0913] 32. The process of any one of clauses 24 to 31, wherein the cooling rate is from 15K / h to 30K / h.
[0914] 33. The process of any one of clauses 24 to 32, wherein the cooling rate is from 17K / h to 30K / h.
[0915] 34. The process of any one of clauses 24 to 33, wherein the solvent in the first step 2 is a polar protic solvent or a mixture of polar protic solvents.
[0916] 35. The process according to any one of clauses 24 to 34, wherein the solvent in the first step 2 is selected from the group consisting of ethanol, water, methanol, 2-propanol, and any mixture thereof.
[0917] 36. The process of any one of clauses 24 to 35, wherein the solvent in the first step 2 is a mixture of ethanol and water.
[0918] 37. The process of any one of clauses 24-36, wherein the first step 2 solvent is 20.5-23.5 kg water per 55 kg ORZY-01 and 200-240 kg EtOH per 55 kg ORZY-01.
[0919] 38. The process of any one of clauses 24-37, wherein the first step 2 solvent is 22 kg water per 55 kg ORZY-01 and 220 kg EtOH per 55 kg ORZY-01.
[0920] 39. The process according to any one of clauses 24 to 38, wherein the temperature of the first step 2 is from 60°C to 75°C, such as from 61°C to 74°C, for example, from 62°C to 73°C, for example, from 63°C to 72°C, for example, from 64°C to 71°C, for example, from 65°C to 70°C, for example, 65°C.
[0921] 40. The process according to any one of clauses 24 to 39, wherein the temperature of the second step 2 is from 10°C to 30°C, such as from 11°C to 29°C, for example, from 12°C to 28°C, for example, from 13°C to 27°C, for example, from 14°C to 26°C, for example, from 15°C to 25°C, for example, 20°C.
[0922] 41. The process according to any one of clauses 24 to 40, wherein the temperature of the third step 2 is 45°C to 65°C, for example, 46°C to 64°C, for example, 47°C to 63°C, for example, 48°C to 62°C, for example, 49°C to 61°C, for example, 50°C to 60°C, for example, 51°C to 59°C, for example, 52°C to 58°C, for example, 53°C to 57°C, for example, 54°C to 56°C, for example, 55°C.
[0923] 42. The process of any one of clauses 24-41, wherein the temperature of the third step 2 is maintained for at least 30 minutes, such as at least 60 minutes.
[0924] 43. The process of any one of clauses 24-42, wherein one or more seed crystals of ORZY-03 are added to the vessel prior to step b.
[0925] 44. The process of any one of clauses 24-43, wherein the one or more seed crystals of ORZY-03 have a chiral purity of at least 95%.
[0926] 45. The process of any one of clauses 24 to 44, wherein the mass of the one or more seeds of ORZY-03 is 0.2 to 0.8 kg per 55 kg of ORZY-03, for example, 0.55 kg per 55 kg of ORZY-03.
[0927] 46. The process of any one of clauses 24-45, wherein the first predetermined volume of solvent in the first step 2 is 35-55 kg per 55 kg of ORZY-03.
[0928] 47. The process of any one of clauses 24-46, wherein the first predetermined volume of solvent in the first step 2 is 41-45 kg per 55 kg of ORZY-03.
[0929] 48. ORZY-05, [ka] A process for preparing a) adding a catalytic amount of citric acid to a solution of ORZY-03 in a first Step 3 solvent contained in a vessel; [ka] b) exchanging the solvent of the mixture of step a) from the first step 3 solvent to a second step 3 solvent, wherein the first step 3 solvent is different from the second step 3 solvent; c) adding an approximately stoichiometric amount of citric acid to the mixture obtained in step b) to form a suspension; d) filtering the suspension obtained in step c) to obtain ORZY-04, which is crude ORZY-05; and e) purifying the ORZY-04 of step d) to obtain ORZY-05.
[0930] 49.Furthermore, i) mixing said compound ORZY-03 with an aqueous solution of a base from a first step 3; and ii) extracting the mixture obtained in step a) with the first step 3 solvent to obtain a solution of ORZY-03 in the first step 3 solvent; prior to adding said catalytic amount of citric acid according to step a) of clause 48 to the solution of ORZY-03 in said first step 3 solvent.
[0931] 50. The process of any one of clauses 48-49, further comprising washing the first step 3 solvent one or more times with water, thereby removing one or more by-products from the first step 3 solvent.
[0932] 51. The process of any one of clauses 48-50, further comprising washing the first step 3 solvent one or more times with water after addition of the first step 3 base, thereby removing one or more by-products from the first step 3 solvent.
[0933] 52. a) mixing said compound ORZY-03 with an aqueous solution of said first step 3 base; [ka] b) extracting the mixture obtained in step a) with the solvent of the first step 3; c) adding a catalytic amount of citric acid to the organic phase(s) of step b); d) exchanging the solvent of the mixture of step c) from the first step 3 solvent to the second step 3 solvent; e) adding an approximately stoichiometric amount of citric acid to the mixture obtained in step d) to form a suspension; and 52. The process according to any one of clauses 48 to 51, comprising a step of: f) filtering the suspension obtained in step e) to obtain crude ORZY-05 (ORZY-04).
[0934] 53. The process of any one of clauses 48 to 52, wherein the solvent in the first step 3 is a chlorinated hydrocarbon or a mixture containing a chlorinated hydrocarbon.
[0935] 54. The process according to any one of clauses 48 to 53, wherein the solvent in the first step 3 is dichloromethane or dichloroethane, preferably dichloromethane.
[0936] 55. The process of any one of clauses 48 to 54, wherein the solvent in the second step 3 is a polar protic solvent or a mixture of polar protic solvents.
[0937] 56. The process according to any one of clauses 48 to 55, wherein the solvent in the second step 3 is selected from the group consisting of methanol, water, ethanol, 2-propanol, and any mixture thereof.
[0938] 57. The process of any one of clauses 48 to 56, wherein the solvent in the second step 3 is methanol.
[0939] 58. The process of any one of clauses 48-57, wherein the base in the first step 3 is a carbonate.
[0940] 59. The process of any one of clauses 48-58, wherein the base of the first step 3 is a carbonate selected from the group consisting of K2CO3 and Cs2CO3.
[0941] 60. The process of any one of clauses 48-59, wherein the base in the first step 3 is K2CO3.
[0942] 61. The process of any one of clauses 48 to 60, wherein the aqueous solution of K2CO3 contains 16.8% K2CO3.
[0943] 62. The process of any one of clauses 48-61, wherein the mixture of ORZY-03 and K2CO3 is extracted three times with CH2Cl2.
[0944] 63. The process according to any one of clauses 48 to 62, wherein the solvent exchange from CH2Cl2 to CH3OH comprises the following steps: a. partially distilling the CH2Cl2 solution; b. adding CH3OH to the distilled solution obtained in step a); c. partially distilling the solution obtained in step b); and d. Adding CH3OH to the solution obtained in step c).
[0945] 64. The process of claim 63, wherein the amount distilled in steps a) and c) is at least equivalent to the amount of CH2Cl2 in which the ORZY-03 was dissolved prior to the solvent exchange step.
[0946] 65. The process according to any one of clauses 63-64, further comprising a step of passing the solution obtained after exchanging the solvent from CH2Cl2 to CH3OH through an activated carbon filter.
[0947] 66. The process of any one of clauses 48-65, further comprising a step of drying the ORZY-04.
[0948] 67. The process of clause 66, wherein the drying step comprises drying the ORZY-04 in vacuum at 45° C. for at least 12 hours.
[0949] 68. A process as described in clause 48, comprising the following successive steps: a) mixing the compound ORZY-03 with a 16.8% aqueous solution of K2CO3; [ka] b) extracting the mixture obtained in step a) one or more times, e.g., three times, with CH2Cl2, followed by washing the combined organic phase one or more times with water; c) adding a catalytic amount of citric acid to the organic phase(s) of step b); d) changing the solvent of the mixture of step c) from CH2Cl2 to CH3OH; i. partially distilling the CH2Cl2 solution of step c); ii. adding CHOH to the distilled solution obtained in step i); iii. partially distilling the solution obtained in step ii); and iv. exchanging the solution obtained in step iii) by adding CH3OH; e) passing the solution obtained in step d) through an activated carbon filter; f) adding an approximately stoichiometric amount of citric acid to the mixture obtained in step e) to form a suspension; g) filtering the suspension obtained in step e) to obtain ORZY-04. h) drying the ORZY-04 obtained in step g) in vacuum at 45° C. for at least 12 hours; and i) purifying ORZY-04 from step h) to obtain ORZY-05.
[0950] 69. The process of any one of clauses 48 to 68, wherein the step of purifying ORZY-04 to obtain ORZY-05 comprises recrystallization of ORZY-04.
[0951] 70. The process according to clause 69, wherein the solvent used in the recrystallization is acetone.
[0952] 71. The process according to any one of clauses 69-70, wherein the recrystallization comprises the steps of: a. mixing ORZY-04 with HO and heating the mixture to 70±5° C. until a clear solution is observed; b. cooling the solution produced in step a) to 30±5° C.; c. adding acetone to the solution of step b); d. cooling the mixture of step c) to 0±5° C.; e. stirring the mixture of step d) at 0±10° C. for 12 hours to form a suspension; f. isolating ORZY-05 from the suspension of step e) by filtering the suspension; and Drying the ORZY-05 obtained in step f) in vacuum at 45° C. for at least 12 hours.
[0953] 72. ORZY-01, [ka] and one or more impurities selected from the group consisting of: [ka]
[0954] 73. The composition according to clause 72, wherein (A) is present in an amount of from 0.1% to 0.5% by weight, and / or (B) is present in an amount of from 0.1% to 0.5% by weight.
[0955] 74. A composition according to any one of clauses 72-73, wherein (A) is present in an amount of 0.1% to 0.5% by weight, such as 0.1% to 0.2% by weight, for example 0.2% to 0.3% by weight, such as 0.3% to 0.4% by weight, for example 0.4% to 0.5% by weight.
[0956] 75. A composition according to any one of clauses 72 to 74, wherein (B) is present in an amount of 0.1% to 0.5% by weight, such as 0.1% to 0.2% by weight, for example 0.2% to 0.3% by weight, such as 0.3% to 0.4% by weight, for example 0.4% to 0.5% by weight.
[0957] 76. Arimoclomol citrate (ORZY-05), comprising one or more of the processes defined in any one of the preceding clauses to obtain ORZY-01, ORZY-03, or ORZY-04; [ka] Preparation process.
[0958] 77. Arimoclomol citrate (ORZY-05), [ka] A process for the preparation of a compound comprising the following successive steps: a. The process as defined in any one of clauses 1 to 23 for obtaining ORZY-01; [ka] b. precipitating ORZY-01 with dibenzoyl L-tartaric acid to obtain ORZY-03; [ka] and c. reacting ORZY-03 with a base followed by precipitating the resulting ORZY-03 free base with citric acid to obtain arimoclomol citrate; thereby obtaining arimoclomol citrate.
[0959] 78. Arimoclomol citrate, [ka] A process for the preparation of a compound comprising the following successive steps: a. obtaining ORZY-01; [ka] b.ORZY-03, [ka] the process as defined in any one of clauses 24 to 47 for obtaining c. reacting ORZY-03 with a base followed by precipitating the resulting ORZY-03 free base with citric acid to obtain arimoclomol citrate; thereby obtaining arimoclomol citrate.
[0960] 79. Arimoclomol citrate, [ka] A process for the preparation of a compound comprising the following successive steps: a. obtaining ORZY-01; [ka] b. precipitating ORZY-01 with dibenzoyl L-tartaric acid to obtain ORZY-03; [ka] and c. the process as defined in any one of clauses 48-77 for obtaining ORZY-05; thereby obtaining arimoclomol citrate.
[0961] 80. The process of any one of the preceding clauses, further comprising adding one or more seed crystals of ORZY-01 to the vessel.
[0962] 81. The process of any one of the preceding clauses, further comprising adding one or more seed crystals of ORZY-03 to the vessel.
[0963] 82. The process of any one of the preceding clauses, further comprising adding one or more seed crystals of ORZY-05 to the vessel.
[0964] 83. The process of any one of the preceding clauses, wherein as the first step, one or more seed crystals of ORZY-01 are added to the vessel.
[0965] 84. The process of any one of the preceding clauses, wherein as the first step, one or more seed crystals of ORZY-03 are added to the vessel.
[0966] 85. The process of any one of the preceding clauses, wherein as the first step, one or more seed crystals of ORZY-05 are added to the vessel.
[0967] 86. An oral formulation comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, and at least one pharma- ceutically acceptable excipient.
[0968] 87. The oral formulation according to clause 86, wherein the pharma- ceutically acceptable salt is N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
[0969] 88. An oral formulation according to clause 86 or clause 87, including a capsule.
[0970] 89. An oral formulation according to any one of clauses 86 to 88, comprising a bulking agent.
[0971] 90. An oral formulation according to any one of clauses 86 to 89, comprising a lubricant.
[0972] 91. The oral formulation of any one of clauses 86 to 90, wherein the capsule comprises hydroxypropyl methylcellulose (HPMC), titanium dioxide, and optionally one or more colorants.
[0973] 92. The oral formulation of any one of clauses 86-91, wherein the filler is microcrystalline cellulose (MCC).
[0974] 93. The oral formulation of any one of clauses 86-92, wherein the lubricant is magnesium stearate.
[0975] 94. The oral formulation according to any one of clauses 86 to 93, wherein the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is present in a dosage of from about 50 mg to about 500 mg.
[0976] 95. The oral formulation of any one of clauses 86-94, wherein the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, is present in a dose of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0977] 96. The oral formulation of any one of clauses 86-94, wherein the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is present in a dosage of about 75 mg, about 100 mg, about 150 mg, about 200 mg, or about 400 mg.
[0978] 97. The oral formulation according to any one of clauses 86 to 96, comprising about 20% to about 60% w / w of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0979] 98. The oral formulation according to any one of clauses 86 to 97, comprising about 26.3% or about 52.6% w / w of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof.
[0980] 99. The oral formulation according to any one of clauses 86 to 98, comprising about 40% to about 80% w / w microcrystalline cellulose.
[0981] 100. An oral formulation according to any one of clauses 86 to 99, comprising about 73.2% or about 46.9% w / w microcrystalline cellulose.
[0982] 101. The oral formulation according to any one of clauses 86 to 100, comprising from about 0.0% to about 1.0% magnesium stearate.
[0983] 102. An oral formulation according to any one of clauses 86 to 101, comprising about 0.5% magnesium stearate.
[0984] 103. A pharmaceutical composition comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, having a purity of 98.0% or greater as measured by HPLC.
[0985] 104. The pharmaceutical composition according to clause 103, comprising less than 2% of an impurity selected from N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide or a pharma- ceutically acceptable salt thereof, methyl (Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide or a pharma- ceutically acceptable salt thereof, or N-nitrosopiperidine, and combinations thereof.
[0986] 105. A unit dosage form of a pharmaceutical composition according to clause 103 or clause 104 and a pharma- ceutically acceptable carrier or excipient.
[0987] 106. A unit dosage form according to clause 105, comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 50 mg to about 500 mg.
[0988] 107. A unit dosage form according to clause 105 or an oral formulation according to clause 49 comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of about 47 mg, about 62 mg, about 93 mg, or about 124 mg.
[0989] 108. A kit comprising a unit dosage form according to any one of clauses 105 to 107 and instructions for administration.
[0990] 109. The kit of clause 108, further comprising prescribing information and / or a plurality of unit doses.
[0991] 110. A method for treating or preventing Niemann-Pick disease, type C, in a subject in need thereof, wherein the subject is administered a therapeutically effective amount of an oral formulation, pharmaceutical composition, or unit dose described in any one of clauses 86 to 107.
[0992] 111. An oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 86 to 107 for use in the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0993] 112. Use of an oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 86 to 107 for use in the manufacture of a medicament for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0994] 113. Use of an oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 86 to 107 for the treatment or prevention of Niemann-Pick disease, type C, in a subject in need thereof.
[0995] 114. A method for use, an oral formulation, a pharmaceutical composition, or a unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 113, wherein said oral formulation, pharmaceutical composition, or unit dose is administered three times a day.
[0996] 115. A method for use, an oral formulation, a pharmaceutical composition, or a unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein said oral formulation, pharmaceutical composition, or unit dose is administered to a pediatric subject having a body weight of about 8 kg to about 15 kg.
[0997] 116. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 115, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 47 mg.
[0998] 117. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 115, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 75 mg.
[0999] 118. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, wherein said oral formulation, pharmaceutical composition, or unit dose is administered to a subject having a body weight of more than about 15 kg to about 30 kg.
[1000] 119. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 118, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 62 mg.
[1001] 120. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 118, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 100 mg.
[1002] 121. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, wherein said oral formulation, pharmaceutical composition, or unit dose is administered to a subject having a body weight of more than about 30 kg to about 55 kg.
[1003] 122. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 121, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 93 mg.
[1004] 123. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 121, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 150 mg.
[1005] 124. A method for use, an oral formulation, a pharmaceutical composition, or a unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, wherein said oral formulation, pharmaceutical composition, or unit dose is administered to a subject having a body weight of more than about 55 kg.
[1006] 125. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 124, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 124 mg.
[1007] 126. The method for use, oral formulation, pharmaceutical composition, or unit dose, or use of said oral formulation, pharmaceutical composition, or unit dose according to clause 124, wherein said oral formulation, pharmaceutical composition, or unit dose is administered in a dose of 200 mg.
[1008] 127. A method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 126, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein at least about 85% of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, dissolves in solution in about 15 minutes.
[1009] 128. A method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 127, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the capsule components are mixed with a liquid for oral administration as a liquid.
[1010] 129. The geometric mean C of the composition after a single dose max But, C max 1749 (CV 49%) ng / mL.
[1011] 130. AUC of the composition after a single dose 0-8時間 But AUC 0-8時間 5317 (CV17%) h·ng / mL.
[1012] 131. AUC of the composition after a single dose 0-無限大 But AUC 0-無限大6331 (CV 17%) h ng / mL.
[1013] 132. The geometric mean C of the composition after administration max,定常状態 But, C max,定常状態 2090 (CV23%) ng / mL.
[1014] 133. AUC of the composition after administration 0-8時間,定常状態 But AUC 0-8時間,定常状態 7207 (CV 19%) h ng / mL.
[1015] 134. A method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 129 to 133, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the N-[(2R,Z)-2-hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxide, or a pharma- ceutically acceptable salt thereof, is measured in plasma.
[1016] 135. The geometric mean C of the composition at steady state max,定常状態 However, in a human weighing about 8 kg to about 15 kg, after administration of the composition, max,定常状態 115. The method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the IL-10 concentration is within about 80.00% to about 125.00% of 533 ng / mL (the 5th and 95th percentiles of 368 to 770 ng / mL).
[1017] 136. AUC of the composition 0-8時間,定常状態 However, in a human weighing about 8 kg to about 15 kg, after administration of the composition, AUC 0-8時間,定常状態 115. The method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the IL-10 concentration is within about 80.00% to about 125.00% of 2916 h·ng / mL (the 5th and 95th percentiles of 1924 to 4436 h·ng / mL).
[1018] 137. The geometric mean C of the composition at steady state max,定常状態 However, in a human weighing more than about 15 kg to about 30 kg, after administration of the composition, max,定常状態 593 ng / mL (5th and 95th percentiles of 395 to 878 ng / mL).
[1019] 138. AUC of the composition 0-8時間,定常状態 However, in a human weighing more than about 15 kg to about 30 kg, after administration of the composition, AUC 0-8時間,定常状態 115. The method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the IL-10 concentration is within about 80.00% to about 125.00% of 3043 h·ng / mL (the 5th and 95th percentiles of 1938 to 4763 h·ng / mL).
[1020] 139. The geometric mean C of the composition at steady state max,定常状態 However, in a human weighing more than about 30 kg to about 55 kg, after administration of the composition, max,定常状態115. The method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the IL-10 concentration is within about 80.00% to about 125.00% of 679 ng / mL (5th and 95th percentiles of 450 to 1024 ng / mL).
[1021] 140. AUC of the composition 0-8時間,定常状態 However, in a human weighing more than about 30 kg to about 55 kg, after administration of the composition, AUC 0-8時間,定常状態 115. The method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the IL-10 concentration is within about 80.00% to about 125.00% of 3149 h·ng / mL (the 5th and 95th percentiles of 2010 to 4855 h·ng / mL).
[1022] 141. The geometric mean C of the composition at steady state max,定常状態 However, after administration of the composition, in a human weighing more than about 55 kg, max,定常状態 115. The method for use, oral formulation, pharmaceutical composition, or unit dose according to any one of clauses 110 to 114, or use of said oral formulation, pharmaceutical composition, or unit dose, wherein the IL-10 concentration is within about 80.00% to about 125.00% of 743 ng / mL (5th and 95th percentiles of 479 to 743 ng / mL).
[1023] 142. AUC of the composition 0-8時間,定常状態 However, in a human weighing more than about 55 kg, after administration of the composition, AUC 0-8時...
Claims
1. N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in an enantiomeric excess (ee) of at least 94%; Pharmaceutical compositions.
2. 2. The pharmaceutical composition of claim 1, wherein the ee of the N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate is at least 95%, at least 96%, at least 97%, or at least 98%.
3. a) N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate with at least 94% ee, e.g., at least 95% ee, e.g., at least 96% ee, e.g., at least 97% ee, e.g., at least 98% ee; and b) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; The pharmaceutical composition according to any one of claims 1 to 2, comprising:
4. a) N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate with at least 94% ee, e.g., at least 95% ee, e.g., at least 96% ee, e.g., at least 97% ee, e.g., at least 98% ee; b) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof; and c) less than 2 ppm N-nitrosopiperidine The pharmaceutical composition according to any one of claims 1 to 3, comprising:
5. a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof; and c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutical acceptable salt thereof; The pharmaceutical composition according to any one of claims 1 to 4, comprising:
6. a) at least 98.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 1.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof; and d) less than 2 ppm N-nitrosopiperidine The pharmaceutical composition according to any one of claims 1 to 5, comprising:
7. a) at least 99.0% N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate, and b) 0.9% or less of N-{[(2S)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof; c) 0.1% or less of methyl(Z)-N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidate 1-oxide, or a pharma- ceutically acceptable salt thereof; and d) less than 2 ppm N-nitrosopiperidine The pharmaceutical composition according to any one of claims 1 to 6, comprising:
8. A pharmaceutical composition according to any one of claims 1 to 7, comprising less than 2 ppm N-nitrosopiperidine, for example less than 1.6 ppm N-nitrosopiperidine, for example less than 1 ppm N-nitrosopiperidine, for example less than 0.8 ppm N-nitrosopiperidine, for example no detectable N-nitrosopiperidine.
9. An oral formulation comprising a pharmaceutical composition as defined in any one of claims 1 to 8 and at least one pharma- ceutically acceptable excipient.
10. The oral formulation of claim 9, comprising 20% to 60% w / w of N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate.
11. A unit dosage form of a pharmaceutical composition as defined in any one of claims 1 to 8 and a pharma- ceutically acceptable carrier or excipient.
12. 12. The oral formulation of any one of claims 9 to 10, or the unit dosage form of claim 11, comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide, or a pharma- ceutically acceptable salt thereof, in a dose of 50 mg to 500 mg.
13. 12. The oral formulation of any one of claims 9 to 10, or the unit dosage form of claim 11, comprising N-{[(2R)-2-hydroxy-3-piperidin-1-ylpropyl]oxy}pyridine-3-carboximidoyl chloride 1-oxide citrate in a dosage of 47 mg, 62 mg, 93 mg, or 124 mg.
14. A pharmaceutical composition according to any one of claims 1 to 8 or an oral formulation or unit dosage form according to any one of claims 9 to 13 for use in the treatment of Niemann-Pick disease, type C.
